document incorporate reference document proxy statement annual meeting shareholder hold file iii security exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information item disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule item summary signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner spinoff organon june merck complete spinoff spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan table content product sale total company sale include sale company pharmaceutical product sale animal health product follow million total sale pharmaceutical keytruda gardasilgardasil januviajanumet proquadmmr iivarivax bridion alliance revenue lynparza molnupiravir pneumovax simponi rotateq isentressisentress alliance revenue lenvima animal health livestock companion animal revenue alliance revenue represent merck share profit product sale net cost sale commercialization cost revenue primarily comprise thirdparty manufacture sale miscellaneous corporate revenue include revenue hedging activity pharmaceutical pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder human health vaccine product consist preventive pediatric adolescent adult vaccine certain product company franchise follow oncology keytruda pembrolizumab company antipd program death receptor therapy monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer solid tumor include msihdmmr colorectal cancer crc primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh cancer solid tumor urothelial carcinoma include nonmuscle invasive bladder cancer keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy human epidermal growth factor herpositive gastric gej adenocarcinoma combination platinumand fluoropyrimidinebase chemotherapy esophageal gej carcinoma combination chemotherapy bevacizumab cervical cancer combination chemotherapy triplenegative breast cancer tnbc combination axitinib advance renal cell carcinoma rcc combination lenvatinib endometrial carcinoma rcc keytruda approve certain patient highrisk earlystage tnbc combination chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery keytruda approve monotherapy adjuvant treatment certain patient rcc addition company recognize alliance revenue relate sale lynparza olaparib oral poly adpribose polymerase parp inhibitor certain type advance ovarian breast pancreatic prostate cancer lenvima lenvatinib certain type table content thyroid cancer hepatocellular carcinoma combination everolimus certain patient rcc combination keytruda certain patient endometrial carcinoma rcc vaccines gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child vaqta hepatitis vaccine inactivated indicate prevention disease cause hepatitis virus person month age old hospital acute care bridion sugammadex injection medication reversal type neuromuscular block agent surgery prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipient allogeneic hematopoietic stem cell transplant primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infection noxafil posaconazole antifungal agent prevention certain invasive fungal infection cancida caspofungin acetate injection antifungal agent treatment certain fungal infection invanz ertapenem injection antibiotic treatment certain bacterial infection zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease remicade infliximab treatment inflammatory disease company market europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicate treatment insomnia characterize difficulty sleep onset andor sleep maintenance virology molnupiravir investigational oral antiviral covid medicine isentressisentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection cardiovascular adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension verquvo vericiguat medicine reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic certain adult symptomatic chronic heart failure reduce ejection fraction diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete animal health animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine health management solution service extensive suite digitally connect identification traceability monitoring product principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory table content drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine exzolt systemic treatment poultry red mite infestation slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solution animal identification monitor traceability companion animal product bravecto line oral topical parasitic control product include original bravecto fluralaner product dog cat week bravecto fluralaner onemonth monthly product dog bravecto plus fluralanermoxidectin twomonth product cat sentinel line oral parasitic product dog include sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine line flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabete mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broad spectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line horse scalibor deltamethrinexspot protect bite flea tick mosquitoe sandfly sure petcare product companion animal identification wellbee include microchip pet recovery system home discussion sale company product item management discussion analysis financial condition result operation product approval authorization set forth summary significant product approval authorization receive company product date approval european commission approve keytruda monotherapy firstline treatment adult january patient msih dmmr crc approve keytruda monotherapy treatment adult pediatric patient age year old relapse refractory chl fail autologous stem cell transplant asct follow march prior therapy asct treatment option food drug administration fda approve keytruda combination platinum fluoropyrimidinebase chemotherapy treatment patient locally advanced metastatic march esophageal gej tumor epicenter centimeter gej carcinoma keytruda amenable surgical resection definitive chemoradiation fda approve keytruda combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy firstline treatment patient locally advanced unresectable metastatic herpositive gastric gej adenocarcinoma chinas national medical products administration nmpa approve keytruda monotherapy firstline treatment patient unresectable metastatic msih dmmr crc kras nras june braf wildtype table content approve keytruda combination platinum fluoropyrimidinebase chemotherapy firstline treatment patient locally advance unresectable metastatic carcinoma june esophagus hernegative gej adenocarcinoma adult tumor express pdl combine positive score cp fda approve keytruda monotherapy treatment patient locally advanced cscc july curable surgery radiation fda approve keytruda plus lenvima treatment patient advance endometrial carcinoma msih dmmr disease progression follow prior systemic therapy july set candidate curative surgery radiation fda approve keytruda treatment patient highrisk earlystage tnbc combination july chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery fda approve keytruda treatment patient locally advanced metastatic urothelial august carcinoma eligible platinumcontaine chemotherapy japan pharmaceuticals medical devices agency pmda approve keytruda treatment patient pdlpositive hormone receptornegative hernegative inoperable recurrent august breast cancer keytruda pmda approve keytruda treatment patient unresectable advanced recurrent msih august crc fda approve keytruda plus lenvima firstline treatment adult patient advance rcc august nmpa approve keytruda combination platinum fluoropyrimidinebase chemotherapy firstline treatment patient locally advance unresectable metastatic carcinoma september esophageal gej fda approve keytruda combination chemotherapy bevacizumab treatment patient persistent recurrent metastatic cervical cancer tumor express pdl october cps determine fdaapproved test approve keytruda combination chemotherapy firstline treatment locally recurrent unresectable metastatic tnbc adult tumor express pdl cps october receive prior chemotherapy metastatic disease fda approve keytruda adjuvant treatment patient rcc intermediatehigh high november risk recurrence follow nephrectomy follow nephrectomy resection metastatic lesion approve keytruda plus lenvima firstline treatment adult patient advance rcc november table content approve keytruda plus lenvima treatment advanced recurrent endometrial carcinoma adult disease progression follow prior treatment platinumcontaine november therapy set candidate curative surgery radiation pmda approve keytruda combination chemotherapy fluorouracil plus cisplatin november firstline treatment patient radically unresectable advanced recurrent esophageal carcinoma fda approve keytruda monotherapy adjuvant treatment adult pediatric year keytruda old patient stage iib iic melanoma follow complete resection fda expand indication keytruda adjuvant treatment stage iii melanoma follow complete december resection include pediatric patient year old japans ministry health labor welfare mhlw approve keytruda combination lenvima treatment patient unresectable advanced recurrent endometrial carcinoma december progress cancer chemotherapy nmpa approve lynparza monotherapy treatment adult patient germline somatic lynparza june brcamutated metastatic castrationresistant prostate cancer progress follow prior treatment include new hormonal agent abiraterone enzalutamide fda grant emergency use authorization eua molnupiravir treat mild moderate covid adult positive result direct sarscov viral test high risk progression severe covid include hospitalization death alternative covid december treatment option authorize fda accessible clinically appropriate molnupiravir mhlw grant molnupiravir special approval emergency treatment infectious disease december cause sarscov fda approve vaxneuvance active immunization prevention invasive disease cause streptococcus pneumoniae serotype july adult year age old vaxneuvance approve vaxneuvance active immunization prevention invasive disease pneumonia cause streptococcus pneumoniae individual year age old december fda approve verquvo reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous january diuretics adult symptomatic chronic ejection fraction verquvo approve verquvo treatment symptomatic chronic heart failure adult patient july reduce ejection fraction stabilize recent decompensation event require therapy fda approve welireg adult patient von hippellindau vhl disease require therapy welireg august associate rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumor require immediate surgery jointly develop commercialize worldwide collaboration astrazeneca jointly develop commercialize worldwide collaboration ridgeback biopharmaceutical molnupiravir approve fda authorize emergency use jointly develop commercialize worldwide collaboration bayer table content competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company wellpositione compete search technological innovation company active acquire marketing product external alliance license arrangement collaboration refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product competitor product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access change health care system health care reform enact prior year increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government party low health care cost biden administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future continue negatively affect revenue performance united states company face increase pricing pressure manage care organization government agency program negatively affect company sale profit margin include practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act aca federal state government year pursue method reduce cost drug vaccine pay example federal state law require company pay specify rebate medicine reimburse medicaid provide discount medicine purchase certain state federal entity department defense veteran affairs public health service entity hospital serve disproportionate share low income uninsured patient table content additionally consolidation integration health care provider major factor competitive marketplace pharmaceutical product health plan pharmacy benefit manager pbms consolidate few large entity enhance purchasing strength importance private thirdparty insurer government employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain placement unfavorable pricing adversely affect revenue addition formulary tier copay differential private health insurance company selfinsure employer increase costshare require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product require patient fail generic product permit access brand medicine management tool treatment area payor take position multiple brand product therapeutically comparable payor market concentrate pharmaceutical company face great pricing pressure private thirdparty payor order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase average discount company portfolio date company gross sale reduce result rebate discount return legislative change congress actively consider multiple version drug pricing legislation significantly impact brand pharmaceutical manufacturer legislation implement government negotiation plan certain product cover medicare parts institute financial penalty price increase inflation redesign medicare program include cap patient pocket cost realign liability cost benefit manufacturer health plan government unclear legislation pass congress remain uncertain proposal include future federal legislative proposal directly indirectly affect company congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin possible manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck future drug high medicaid utilization rebate exposure amp company face increase pricing pressure state look exert great influence price prescription drug number state pass pharmaceutical price cost transparency law law typically require manufacturer report certain product price information financial datum state law require manufacturer provide advance notification price increase company expect state continue focus pharmaceutical pricing increasingly shift aggressive price control tool prescription drug affordability board authority conduct affordability review establish upper payment limit regulatory change february center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation amp good price metric determine rebate drug manufacturer require pay state medicaid programs december cms issue final rule make significant change requirement effective january final rule change way manufacturer calculate good price relation certain patient support program include coupon phrma pharmaceutical industry trade group company member file complaint challenge rule invalid assert conflict table content plain language medicaid drug rebate statute legal challenge fail impact provision final rule adversely impact company business cash flow result operation financial condition prospect november department health human service office inspector general issue final rule effective january eliminate antikickback statute safe harbor rebate pay medicare plans pbms behalf plan company anticipate effect change way currently contract new framework significantly alter way business plan sponsor pbms behalf plan rulemake establish effective january new safe harbor point sale discount pharmacy counter new safe harbor certain service arrangement pharmaceutical manufacturer pbms congress delay implementation final rule january pende federal legislation repeal entirely pharmaceutical industry consider potential source saving legislative administrative proposal debate enact type revenue generating cost saving proposal include additional direct price control european union effort health care cost containment remain intense european union company face competitive pricing pressure result generic biosimilar drug addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug reference pricing compare product price market external reference pricing compare product price product national class internal reference pricing authority use price datum set new local price brandname drug include company drug guideline examine reference pricing usually set local market change pursuant local regulation member states establish freeprice system regulate pricing drug profit control plan seek negotiate set price base costeffectiveness product assessment offer therapeutic benefit product relevant class downward pressure health care cost general particularly prescription drug intense result increasingly high barrier erect entry new product member states crossborder import lowprice market exert competitive pressure reduce pricing member state additionally member states power restrict range pharmaceutical product national health insurance system provide reimbursement pricing reimbursement plan vary widely member state member state member state provide drug product marketed reimbursement price agree member states require completion additional study compare cost effectiveness particular product candidate available therapy socalle health technology assessment hta order obtain reimbursement pricing approval hta pharmaceutical product increasingly common price reimbursement procedure member states hta process govern national law country involve assessment costeffectiveness public health impact therapeutic impact andor economic social impact use give pharmaceutical product national health care system individual country conduct ultimately hta measure add value new health technology compare exist one outcome hta specific pharmaceutical product influence pricing reimbursement status grant pharmaceutical product regulatory authority individual member states negative hta company product mean product reimbursable force company reduce reimbursement price offer discount rebate negative hta leading recognize hta body undermine company ability obtain reimbursement relevant product outside jurisdiction example member states develop hta mechanism rely extent hta perform country develop hta framework inform pricing reimbursement decision hta procedure require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement table content obtain reimbursement pricing approval member states company require conduct study compare cost effectiveness company product candidate therapy consider local standard care assurance member state allow favorable pricing reimbursement market access condition company product feasible conduct additional costeffectiveness study require brexit united kingdom hold referendum voter approve exit commonly refer brexit result referendum subsequent negotiation leave january transitional period apply january december period operate member state continue participate customs union allow freedom movement people good announce december agree trade cooperation agreement tca tca set new arrangement trade good include medicine vaccine allow good continue flow tca sign december apply provisionally january enter force result tca company believe operation materially adversely affect brexit japan japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore government order repricing specific product determine use product exceed certain threshold define applicable repricing rule governmentmandate price reduction occur april china companys business china grow rapidly past year importance china company overall pharmaceutical vaccine business increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company current inline product absence trade impediment adverse pricing control recent year chinese government introduce implement number structural reform accelerate shift innovative product reduce cost multiple new policy introduce government improve access new innovation reduce complexity regulatory filing accelerate review approval process lead significant increase number new product approve year mechanism drug add government national reimbursement drug list nrdl evolve inclusion require price negotiation impact outlook market select brand drug add nrdl average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution volume base procurement vbp government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward emerge market company focus emerge market addition china continue government emerge market focus constrain health care cost enact price control measure impact intellectual property include exceptional case threat compulsory license especially covid vaccine drug aim pressure price innovative pharmaceutical result constrain market access innovative medicine company anticipate pricing pressure market access challenge continue future vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability change trade sanction embargo significant currency fluctuation control financial crisis limit change table content availability fund health care credit worthiness health care partner hospital covid development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address global cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe wellpositione respond evolve health care environment market force regulation pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market time fda commit expedite development review product bear breakthrough therapy designation accelerate regulatory review process medicine designation fda undertake effort bring generic competition market efficiently timely manner adopt directive legislation concern classification approval marketing labeling advertising manufacture wholesale distribution integrity supply chain pharmacovigilance safety monitor medicinal product human use provide mandatory standard supplemented implement additional regulation member states particular regulator approve product subject number postauthorization condition example typical postauthorization commitment include additional pharmacovigilance conduct clinical trial establishment patient registry physician patient education control distribution prescribing arrangement non compliance postauthorization condition pharmacovigilance obligation lead regulatory action include variation suspension withdrawal marketing authorization enforcement regulatory action include imposition financial penalty company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize collaboration key stakeholder role play help ensure science advance health care product accessible affordable company commit ensure reliable safe global supply quality medicine vaccine develop testing implement innovative solution address barrier access affordability medicine vaccine company approach design enable serve great number patient today table content meeting need patient future company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition innovative social investment include philanthropic program impact investing merck help strengthen health system build capacity particularly resource community merck patient assistance program provide medicine adult vaccine free people prescription drug health insurance coverage company assistance afford merck medicine vaccines merck fund merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent grantmaking organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include general data protection regulation gdpr go effect impose penalty global revenue gdpr related implement law individual member states govern collection use personal health datum personal datum gdpr increase responsibility liability relation personal datum company process impose number strict obligation restriction ability process include collection analysis transfer personal datum include health datum clinical trial adverse event report gdpr include requirement relate consent individual personal data relate information provide individual prior process personal datum personal health datum notification datum processing obligation national datum protection authority security confidentiality personal datum gdpr prohibits transfer personal data country outside consider provide adequate level data protection include datum controller meet specific requirement follow schrems decision court justice july considerable uncertainty permissibility international data transfer gdpr light implication decision company face difficulty transfer personal datum country failure comply requirement gdpr related national datum protection law member states result significant monetary fine administrative penalty civil liability claim individual personal datum process datum protection authority different member state implement certain variation enforce gdpr national datum protection law differently introduce additional national regulation guideline add complexity process personal datum guidance develop level national level individual member state concern implementation compliance practice update revise grow trend require public disclosure clinical trial datum add complexity obligation relate processing health datum clinical trial fail comply obligation lead government enforcement action significant penalty company harm reputation adversely impact business operating result uncertainty interplay different regulatory framework add complexity company face regard datum protection regulation august china national people congress pass personal information protection law pipl aim standardize handle personal information china effective november pipl currently apply process personal information natural person china process personal information outside china purpose provide product service china analyze activity individual china similar gdpr pipl contain unique requirement find gdpr table content company develop implement comprehensive plan ensure compliance pipl relate data localization crossborder transfer complete pende forthcoming guidance cyberspace administration china additional law regulation enact california consumer privacy act europe asia latin america increase enforcement litigation activity develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolving requirement risk facilitate transfer personal information international border distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pbms institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer patent trademark license patent protection consider aggregate material importance company marketing product major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term period patent product regulatory review fda provide additional month pediatric market exclusivity attach product supplementary protection certificate spc japan provide additional term pediatric study attach market exclusivity unrelated patent term patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection japan china include potential patent term extension pte spc indicate follow market product table content product year expiration year expiration year expiration japan year expiration china januvia janumet janumet isentress simponi lenvima spc expire bridion expired bravecto pende pte patent spcs gardasil expire expire gardasil patent spc keytruda lynparza pending pte patent spcs zerbaxa patent spc pende pte adempas belsomra prevymis pende pte patent spc segluromet pende pte patent spc steglatro pende pte patent spc steglujan pende pte patent spc verquvo pende pte vaxneuvance pende pte patent delstrigo pende pte patent spc pifeltro pende pte patent spc recarbrio pende pte welireg pende pte note compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability currently market approval date represent expiration date follow country france germany italy spain major market spc application file grant major markets patent expiry date spc expiry date list pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date eligible month pediatric exclusivity expiry date reflect approve product includes grant pte tablet japan company marketing right japan china distribution agreement janssen pharmaceuticals inc expire october global strategic oncology collaboration eisai ltd global strategic oncology collaboration astrazeneca commercialize worldwide collaboration bayer company marketing right commercialize promote worldwide japan collaboration pfizer inc company marketing right japan company marketing right japan china table content company follow key patent protection drug candidate review fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration gefapixant company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration islatravir sotatercept mka doravirine islatravir pende pte doravirine mka quavonlimab pembrolizumab mka vibostolimab pembrolizumab mka favezelimab pembrolizumab clesrovimab molnupiravir receive emergency use authorization fda treatment highrisk adult mild moderate covid note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product expiration compound patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive laterexpire patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek country reform patent relevant law implementation international treaty information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely table content royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program december approximately people employ company research activity company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit ensure externally source program remain important component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease metabolic disease infectious disease neuroscience respiratory disease vaccine development human health product industry practice government regulation foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market table content vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review special designation grant give application product designate breakthrough therapy eligible priority review covid public health crisis secretary health human service exercise statutory authority determine public health emergency exist declare circumstance justify emergency use drug biological product authorize fda effect declaration enable fda issue emergency use authorization euas permit distribution use specific medical product absent ndabla submission approval include product treat prevent disease condition cause sarscov virus subject term euas fda certain finding grant eua include reasonable believe base totality evidence drug biologic effective know potential benefit term eua outweigh know potential risk additionally fda find adequate approve available alternative emergency use fda revise revoke eua circumstance justify issuance long exist criterion issuance long meet circumstance revision revocation appropriate protect public health safety primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure table content file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member states outside company submit marketing application national regulatory authority example ministry health labour welfare japan national medical products administration china health canada agncia nacional vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review internationally latestage clinical development molnupiravir investigational oral antiviral medicine treatment mild moderate covid adult risk progress severe disease merck develop molnupiravir collaboration ridgeback biotherapeutic fda grant emergency use authorization eua molnupiravir december update february authorize molnupiravir treatment mild moderate covid adult positive result direct sarscov viral test high risk progression severe covid include hospitalization death alternative covid treatment option approve authorize fda accessible clinically appropriate authorization base phase moveout trial molnupiravir approve use authorize duration declaration circumstance exist justify authorization emergency use food drug cosmetic act authorization terminate revoke soon molnupiravir receive conditional marketing authorization special approval emergency japan november ema issue positive scientific opinion molnupiravir intend support national decisionmake possible use molnupiravir prior marketing authorization october ema initiate rolling review molnupiravir treatment covid adult merck plans work committee medicinal product human use ema complete rolling review process facilitate initiate formal review maa application regulatory body worldwide underway molnupiravir evaluate postexposure prophylaxis phase moveahead trial evaluate efficacy safety molnupiravir prevention covid adult reside person covid previously announce datum movein clinical trial indicate molnupiravir unlikely demonstrate clinical benefit hospitalize patient generally long duration symptom prior study entry decision proceed phase gefapixant investigational orally administer selective receptor antagonist treatment refractory chronic cough unexplained chronic cough adult review fda nda gefapixant base result cough cough clinical trial january fda issue complete response letter crl merck nda gefapixant crl fda request additional information relate measurement efficacy crl relate safety gefapixant merck reviewing letter consider step gefapixant review review period extend pende receipt additional information company investigational valent pneumococcal conjugate vaccine review japan use adult approve use adult market vaxneuvance vaxneuvance priority review fda prevention invasive pneumococcal disease child week year age fda grant priority review medicine vaccine approve provide significant improvement safety effectiveness treatment prevention condition fda set pdufa date april supplemental bla support result phase phase clinical study pediatric population include infant child adolescent table content keytruda antipd therapy approve treatment cancer clinical development expand indication approval result broad clinical development program currently consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial currently phase clinical development trial plan cancer keytruda review adjuvant treatment adult pediatric year old patient stage iib iic melanoma follow complete resection base datum phase keynote trial keytruda review japan adjuvant treatment patient rcc intermediatehigh high risk recurrence follow nephrectomy surgical removal kidney base datum phase keynote trial keytruda review fda treatment patient advance endometrial cancer msih dmmr disease progression follow prior systemic therapy set candidate curative surgery radiation submission base datum keynote trial fda set pdufa date march keytruda review treatment unresectable metastatic msih dmmr colorectal endometrial gastric small intestine biliary pancreatic cancer adult receive prior therapy propose indication base result keynote keynote trial keytruda combination chemotherapy review japan treatment patient highrisk earlystage tnbc neoadjuvant treatment single agent adjuvant treatment surgery base datum keynote trial keytruda review japan treatment adult patient advance recurrent tmbh solid tumor progress chemotherapy limited use difficult treat standard care base keynote trial keytruda combination chemotherapy bevacizumab review japan firstline treatment patient persistent recurrent metastatic cervical cancer base keynote trial january merck european organisation research treatment cancer european thoracic oncology platform announce phase keynote trial investigate keytruda meet dual primary endpoint diseasefree survival dfs adjuvant treatment patient stage ibiiia nsclc follow surgical resection regardless pdl expression base interim analysis review conduct independent datum monitor committee adjuvant treatment keytruda result statistically significant clinically meaningful improvement dfs compare placebo allcomer population patient stage ibiiia nsclc interim analysis improvement dfs patient tumor express pdl tumor proportion score tps treat keytruda compare placebo dual primary endpoint meet statistical significance prespecifie statistical plan trial continue analyze dfs patient tumor express high level pdl tps evaluate overall survival key secondary endpoint result present upcoming medical meeting submit regulatory authority lynparza oral parp inhibitor currently approve certain type advance ovarian breast pancreatic prostate cancer develop multiple cancer type collaboration astrazeneca plc november fda accept priority review supplemental nda lynparza adjuvant treatment patient brcamutate human epidermal growth factor receptor hernegative highrisk earlystage breast cancer treat chemotherapy surgery base result phase olympia trial fda set pdufa date quarter table content indication review lynparza review treatment certain patient metastatic castrationresistant prostate cancer base propel clinical trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai ltd eisai merck eisai study keytruda plus lenvima combination leap lenvatinib pembrolizumab clinical program include phase study different tumor type biliary cancer crc endometrial carcinoma esophageal cancer gastric cancer glioblastoma hcc hnscc melanoma pancreatic cancer prostate cancer nsclc sclc rcc july merck eisai announce fda issue crl merck eisais application seek accelerate approval line treatment patient unresectable hcc base keynotestudy trial ahead pdufa action date merck eisais application combination therapy approve base randomize control trial demonstrate improvement overall survival versus standardofcare treatment consequently crl state merck eisais application provide evidence keytruda combination lenvima represent meaningful advantage available therapy treatment unresectable metastatic hcc prior systemic therapy advanced disease application keynotestudy long meet criterion accelerate approval company plan work fda appropriate step include conduct wellcontrolle clinical trial demonstrate substantial evidence effectiveness clinical benefit combination leap phase trial evaluate keytruda plus lenvima combination firstline treatment advance hcc currently underway fully enrol crl impact current approve indication keytruda lenvima merck eisai stop leap phase study evaluate firstline treatment lenvima combination keytruda participant metastatic squamous nonsquamous nsclc tumor pdl positive egfr alk genomic tumor aberration trial discontinue follow recommendation external datum monitor committee edmc meet schedule assess safety futility edmc determined study meet criterion declare futility benefitrisk profile combination support continue trial merck eisai close leap enrollment leap phase study evaluate lenvima combination keytruda line treatment patient platinumineligible urothelial carcinoma enrollment closed follow recommendation edmc meet schedule assess safety futility edmc determine benefitrisk profile combination support continue trial improvement outcome favor combination unlikely high initially hypothesize company program phase clinical development mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab evaluate treatment rcc subcutaneous pembrolizumab evaluate comparability intravenous formulation nsclc mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab evaluate treatment crc welireg belzutifan hypoxiainducible factor hif inhibitor evaluate supplemental indication treatment patient rcc tukysa small molecule tyrosine kinase inhibitor treatment herpositive cancer development treatment breast cancer september seagen grant merck exclusive license enter codevelopment agreement merck accelerate global reach tukysa mka coformulation vibostolimab antitigit therapy pembrolizumab evaluate treatment nsclc december merck announce fda place clinical hold investigational new drug application oral implant formulation islatravir hiv preexposure prophylaxis table content prep injectable formulation islatravir hiv treatment prophylaxis oral doravirineislatravir mka hiv oncedaily treatment regimen fda clinical hold base observation decrease total lymphocyte tcell count participant receive islatravir clinical study merck previously announce stop dosing phase imaginedr clinical trial islatravir combination pause enrollment oncemonthly phase prep study fdas clinical hold new study initiate additionally merck gilead decision stop dose participant phase clinical study evaluate oralweekly combination treatment regimen islatravir gilead investigational lenacapavir people live hiv virologically suppress antiretroviral therapy decision follow joint announcement november temporary hold enrollment screening study commence october company assess different dosing islatravir combination lenacapavir provide onceweekly oral therapy option people live hiv merck gilead remain committed collaboration aim develop longacte new treatment option address unmet need people live hiv sotatercept potentially firstinclass therapy treatment pulmonary arterial hypertension pah sotatercept clinical trial addon current standard care treatment pah sotatercept obtain connection merck acquisition acceleron pharma inc clesrovimab respiratory syncytial virus rsv monoclonal antibody evaluate prevention rsv medically attend low respiratory tract infection infant certain child year age april merck announce discontinuation development evaluate treatment hospitalize patient covid merck obtain december acquisition oncoimmune privately hold clinicalstage biopharmaceutical company merck receive feedback fda additional datum need support potential eua application company expect available half give timeline technical clinical regulatory uncertainty availability number medicine patient hospitalize covid need concentrate merck resource accelerate development manufacture viable therapeutic vaccine merck decide discontinue development treatment covid september fda approve update label steglatro steglujan segluromet medicine adult type diabete include primary efficacy safety result vertis trial assess effect steglatro compare placebo cardiovascular outcome adult patient type diabete establish atherosclerotic cardiovascular disease fda issue crl concern company application new indication base additional result vertis trial reduce risk hospitalization heart failure company determine pursue indication chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect cancer additional claim line extension formulation inline product show table content phase phase phase entry date review cancer antiviral covid new molecular entitiesvaccine mlc tae tiu ibg cam nck molnupiravir ant miv kir piravir hematological malignancies mka quavonlimabpembrolizumab cough qla ven oll mnb pembrolizumab mkr kel rup ail pnem umk vef aap ccix inan advance solid tumor biliary september jpn colorectal cutaneous squamous cell august laa nto mel alular gastric smallcelllung hepatocellular certain supplemental filing cce laa ulb prve tit aah ake stage iib iic melanoma lii igm cie mks lel cbu ern llg nma adju kee ety neo oat tle nonsmallcell lung mka favezelimabpembrolizumab msih dmmr endometrial cancer lla nel gimabpembrolizumab mkc wtal reo mber basket renal cell february keynote smo enn nll lung high uis jpa nrly stage triplenegative breast cancer keynote lynparza tumor mutational burdenhigh keynote jpn nonsmallcell lung colorectal august cervical cancer keynote jpn mks rau tun umab vedotin nonsmallcell lung june breast smallcell lung december esophageal mka vibostolimabpembrolizumab gastric nonsmallcell lung april lynparza oea cec lung tae aim brca tat hernegative adjuvant breast cancer olympia prostate esophageal july firstline metastatic prostate cancer mks ell reu gastric december propel biliary head neck february colorectal melanoma march mkh eca heo tic kel dau diseaseassociate tumor toa odl rae vll inu lata ruary tti eam uep ellular carcinoma vaa lead solid tumor pulm mmk kon sts oel ait kan yed ees nen cell carcinoma eno dlo mec ial respiratory syncytial virus gastric clesrovimab november nonsmallcell lung lynparza advance solid tumor vibostolimab melanoma mka vibostolimabpembrolizumab footnote sry develop collaboration cervical endometrial develop combination keytruda esophageal head neck develop monotherapy andor combination keytruda hematological malignancy pre tecellular fda clinical hold lenvima available emergency use authorization pali rela tit coma january fda issue crl merck review crl prostate consider step smallcell lung july fda issue crl mercks eisais application eous squamous cell merck eisai intend submit additional datum available head neck fda melanoma solid tumor approve february cardiovascular chikungunya virus vaccine hiv infection mkb islatravirmk mkd islatravirlenacapavir nonalcoholic steatohepatitis nash overgrowth syndrome miransertib pneumococcal vaccine adult pulmonary arterial hypertension schizophrenia treatment resistant depression table content human capital december company approximately employee worldwide approximately employ include puerto rico additionally approximately thirdparty contractor globally approximately company employee fulltime employee woman individual underrepresented ethnic group comprise approximately workforce company define workforce employee respectively woman comprise member board director additionally company executive team woman approximately company employee represent collective bargaining group company voluntary turnover rate approximately respectively company recognize employee critical meet need patient customer ability excel depend integrity skill diversity employee party contractor include company temporary worker independent contractor freelancer view fulltime equivalent employee exclude outsource service provider talent acquisition company use comprehensive approach ensure recruit retention leadership development goal systematically execute company hire talented leader achieve improved gender parity representation dimension diversity company provide training manager external recruiting organization strategy mitigate unconscious bias candidate selection hiring process addition company utilize comprehensive communication strategy employee brand marketing outreach social medium strategic alliance partnership reach broad pool talent critical business area company hire approximately employee globe channel include company external career site direct passive candidate source diversity partnership employee referral university external source global diversity inclusion diversity inclusion fundamental company success core future innovation company foster globally diverse inclusive workforce employee create environment belong engagement equity empowerment company proactive intentional diversity hire development program advance talent company create competitive advantage leverage diversity inclusion accelerate business performance include foster global supplier diversity integrate diversity inclusion company commercialization strategy leverage employee insight improve performance addition effort company employee business resource group provide opportunity employee active contribute company inclusive culture work talent acquisition development business customer insight social community outreach company diversity goal include increase representation senior management role woman globally blackafrican american iii hispanicslatino december representation senior management role company woman globally blackafrican american iii hispanicslatinos addition company seek maintain exceed current inclusion index score current employee engagement index score senior management role define individual holding vice president senior vice president title inclusion index average favorability score employee response item employee pulse survey manager support inclusion sense belong leader value perspective employee engagement index average favorability score employee response item employee survey table content gender ethnicity performance datum woman workforce woman workforce woman board director woman executive role woman management role member underrepresented ethnic group board director member underrepresented ethnic group executive role member underrepresented ethnic group workforce member underrepresente ethnic group management role new hire female new hire member underrepresented ethnic group selfidentifie company prior period datum restate adjust organon spinoff executive role define individual hold executive vice president title management role define manager direct report executive define note compensation benefit company provide valuable total reward package reflect commitment attract retain motivate talent support employee family stage life company continuously monitor adjust compensation benefit program ensure competitive contemporary helpful engaging support strategic imperative diversity inclusion equity flexibility quality security affordability example company add personal health care concierge service assist employee participate company medical plan health care need align business support cancer care strategy company improve cancer screening benefit add resource provide immediate access lead cancer center excellence employee globally company implement minimum standard week pay parental leave inclusively apply parent company benefit rank quartile fortune company aon benefits index company include seramount previously work mother good company rank consecutive year name seramount good company dad employee wellbee company commit help employee family improve health wellbeing company culture wellbee refer live include program support preventive health emotional financial wellbee physical fitness nutrition design inspire employee pursue enjoy share healthy lifestyle live launch today available country company employee addition company large site offer onsite health clinic provide array service help employee stay include vaccination cancer biometric screening travel medicine advice diagnosis treatment nonoccupational illness injurie health counseling referral company overall employee wellbee program recognize excellence health wellbeing receive recent highestlevel award business group health american heart association covid response company recognize unique responsibility help response covid pandemic committed support protect employee family ensure supply medicine vaccine reach patient contribute scientific expertise development antiviral approach support health care provider community serve company continue provide employee easy regular access information include detail company tracking process guidance hygiene measure travel good practice work home example pandemic support resource program available company employee include pay continuation worker sick expose volunteer policy adjustment enable employee table content medical background volunteer sarscovrelate activity resource prioritize physical mental wellness adjustment medical plan cover covidrelated diagnosis testing treatment backup childcare engage employee company strive foster employee engagement promote safe positive diverse inclusive work environment provide numerous opportunity twoway communication employee company key program initiative include promote global employee engagement survey ongoe pulse check organization interim feedback specific topic foster professional networking collaboration identify provide opportunity volunteer establish positive cooperative business relation designate employee representative talent management development company pursue goal world premier researchbase biopharmaceutical company consistent focus importance continuously develop diverse talented people company current talent management system support companywide performance management leadership development talent review succession plan annual performance review help professional development company employee ensure company workforce align company objective company seeks continuously build skill capability workforce accelerate talent improve performance mitigate risk relevant continuous learning experience include limited building leadership management skill provide technical functional training employee environmental matter environmental sustainability company strive strong environmental steward realize strategy effort need continuously improve company excel increasingly resourceconstraine world company environmental sustainability strategy area focus drive efficiency operation design new product minimize environmental impact reduce impact company upstream downstream value chain company recently adopt set new climate goal address rise expectation customer investor external stakeholder employee environmental impact operation supply chain goal include achieve carbon neutrality greenhouse gas emission operation scope reduce scope greenhouse gas emission baseline reduce value chain scope greenhouse gas emission baseline source renewable energy purchase electricity company absolute greenhouse gas reduction target verify science base target initiative environmental sustainability initiative company include global water use stewardship company global water strategy aim achieve sustainable water management operation supply chain address waterrelate risk access clean water critical human health water key input company manufacture operation company site employ variety technology technique closedloop cool system reuse reverse osmosis reject water reduce company water footprint improve operational performance waste management diversion company continuously strive reduce operational waste generate maximize use environmentally beneficial disposal method recycle compost wastetoenergy product stewardship green sustainable science company product stewardship program focus identify prevent minimize potential safety environmental hazard product life cycle company commit table content understand manage reduce environmental impact product material associate discover produce company green sustainable science program use greenbydesign approach efficient innovative processing method technology company reduce energy water raw material company use companys product reduce waste company generate lower company production cost animal conservation company lead worldwide supplier individual identification realtime datum access advanced analytic animal conservation community enable company produce actionable insight inform recovery action global scale specie range wild fish penguin company provide wild fish conservation monitoring equipment realtime video monitor technology advance fish health welfare technology help promote biodiversity support global need reliable safe source protein management believe expenditure relate initiative material adverse effect company financial condition result operation liquidity capital resource year december company complete inaugural issuance billion sustainability bond billion underwritten bond offer company intend use net proceed sustainability bond offer support project partnership company priority environmental social governance esg area contribute advancement united nations sustainable development goal merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy usage water use greenhouse gas emission environmental regulation remediation company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure material adverse effect company financial condition result operation liquidity capital resource year geographic area information company operation outside conduct primarily subsidiarie sale worldwide subsidiary outside percentage total company sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition table content merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time available information company internet website address merckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec address website secgov addition company provide charge copy annual report include financial statement schedule write request shareholder office secretary merck inc galloping hill road kenilworth usa companys corporate governance guideline charter board director stand committee available company website merckcomcompanyoverviewleadership information available print shareholder request company company environmental social governance esg progress report provide enhanced esg disclosure available company website merckcomcompanyoverviewresponsibility information company esg progress report incorporate reference item risk factor summary risk factor company subject number risk realize materially adversely affect business result operation cash flow financial condition prospect follow summary principal risk factor face company company dependent patent right patent right invalidate circumvent business materially adversely affect company product lose market exclusivity company generally experience significant rapid loss sale product key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection company success dependent successful development marketing new product subject substantial risk company face continue pricing pressure respect product unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result company face intense competition low cost generic product company face intense competition competitor product covidrelate disruption adverse impact company business operation financial performance company unable predict extent table content covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect environmental social governance esg matter impact company business reputation failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company experience difficulty delay manufacture certain product include vaccine company able realize expect benefit investment emerge market company expose market risk fluctuation currency exchange rate interest rate pharmaceutical product develop unexpected safety efficacy concern reliance thirdparty relationship outsource arrangement materially adversely affect company business negative event animal health industry material adverse effect future result operation financial condition biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition health care industry continue subject increase regulation political action company product include product development market company obtain maintain regulatory approval development follow regulatory approval adversely affect sale company product company subject variety international law regulation company subject evolve complex tax law result additional liability affect result operation financial condition adverse outcome current future legal matter negatively affect merck business product liability insurance product limit cost prohibitive unavailable company increasingly dependent sophisticated software application compute infrastructure company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation company target future cyberattack social medium mobile messaging platform present risk challenge list exhaustive company face additional challenge risk investor carefully consider information set forth include follow risk factor decide invest company security table content risk factor risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation cash flow prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result risk relate company business company dependent patent right patent right invalidate circumvent business materially adversely affect patent protection consider aggregate material importance company market human health animal health product major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business successfully assert defend patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company assert defend patent outside include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate nda fda seek market generic form company product prior expiration relevant patent own license company company normally respond assert patent lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation certain foreign market relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company launch commercially successful product replace lose sale addition product measure fair value capitalize connection acquisition experience difficulty market negatively affect product cash flow company recognize material noncash impairment charge respect value product chart list patent protection certain company market product patent protection candidate phase clinical development set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant table content rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial condition prospect januvia janumet lose market exclusivity january januvia janumet lose market exclusivity september china july company anticipate sale januvia janumet market decline substantially loss exclusivity key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company ability generate profit operate cash flow depend largely continue profitability company key product keytruda gardasilgardasil lynparza bravecto bridion particular company oncology portfolio lead keytruda represent substantial portion company revenue growth result company dependence key product event adversely affect product market product significant adverse impact result operation financial condition event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection order remain competitive company like major pharmaceutical company continue launch new product expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop collaboration joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug vaccine result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short table content term long term material adverse effect company business result operation cash flow financial condition prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication anticipate labeling uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition certain collaboration failure successfully develop market new product short term long term material adverse effect company business result operation cash flow financial condition prospect company face continue pricing pressure respect product company face continue pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca iii state activity aim increase price transparency include new law note item competition health care environment change health care system enact health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition large customer receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase company portfolio date company gross sale reduce result rebate discount return outside numerous major market include japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore government order reprice specific product determine use product exceed certain threshold define applicable repricing rule table content company expect pricing pressure continue future unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result company business adversely affect local global economic condition include respect inflation interest rate cost raw material packaging uncertainty global economic geopolitical condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial condition prospect discuss competition health care environment global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market government mandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government party low health care cost company anticipate action additional action future continue negatively affect revenue performance credit economic condition worsen result economic currency impact affect market globally material adverse effect company result addition covid pandemic cause disruption volatility company global supply chain network company experience disruption availability delay shipment raw material packaging relate cost inflation disruption delay cost result company inability meet demand company product company face intense competition low cost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak political pressure reduce spending prescription drug lead legislation measure encourage use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial condition prospect company face intense competition competitor product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use well insurance coverage reimbursement level effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial condition prospect addition product measure fair value capitalize table content connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product covidrelated disruption adverse impact company business operation financial performance company unable predict extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company business financial result negatively impact covidrelated disruption continue duration severity covid pandemic uncertain rapidly change difficult predict degree covidrelate disruption impact company result depend future development company knowledge control include limited duration pandemic severity success action take contain prevent virus treat impact quickly extent normal economic operating condition resume covid pandemic impact company business numerous way expect company human health business comprise largely physicianadministere product revenue negatively impact social distancing measure few visit negatively affect vaccine oncology sale particular estimate negative impact covidrelate disruption merck revenue year approximately billion attributable pharmaceutical segment merck believe global health system patient largely adapt impact covid roughly merck pharmaceutical segment revenue comprise physicianadministered product adversely affect pandemic effect worsen despite company effort manage impact covid pandemic ultimate effect depend factor company knowledge control include duration covid pandemic governmental thirdparty action take contain prevent spread treatment virus mitigate public health economic effect addition future pandemic epidemic similar public health threat present similar risk company business cash flow result operation financial condition prospect company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition extent company operation outside significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement include imposition trade sanction similar restriction government foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease particular february armed conflict escalate russia ukraine possible predict broad consequence conflict include sanction embargo regional instability geopolitical shift adverse effect macroeconomic condition currency exchange rate financial market table content climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect company believe climate change potential negatively affect business result operation cash flow prospect company expose physical risk extreme weather condition rise sea level risk transition lowcarbon economy additional legal regulatory requirement change technology market risk reputational risk social human effect population dislocation harm health wellbeing associate climate change risk acute shortterm chronic longterm adverse impact climate change include increase frequency severity natural disaster extreme weather event hurricane tornado wildfire exacerbate drought flooding extreme heat extreme weather sealevel rise pose physical risk company facility supplier risk include loss incur result physical damage facility loss spoilage inventory business interruption cause natural disaster extreme weather event potential physical impact climate change include reduce access highquality water certain region loss biodiversity impact future product development risk disrupt company operation supply chain result increase cost new legal regulatory requirement enact prevent mitigate adapt implication change climate effect environment regulation differ jurisdiction result company subject new expand carbon pricing taxis increase compliance cost restriction greenhouse gas emission investment new technology increase carbon disclosure transparency upgrade facility meet new building code redesign utility system increase company operating cost include cost electricity energy company company supply chain likely subject transitional risk likely pass increase cost company environmental social governance esg matter impact company business reputation governmental authority nongovernmental organization customer investor external stakeholder employee increasingly sensitive esg concern diversity inclusion climate change water use recyclability recoverability packaging plastic waste focus esg concern lead new requirement result increase cost associate develop manufacturing distribute companys product company ability compete affect change customer preference requirement grow demand environmentally friendly product package supplier practice failure meet customer expectation demand company strive improve esg performance company risk negative stockholder reaction include proxy advisory service damage brand reputation company act responsibly company perceive act responsibly key esg area include equitable access medicine vaccine product quality safety diversity inclusion environmental stewardship support local community corporate governance transparency address human capital factor company operation company meet esg expectation investor customer stakeholder company experience reduced demand product loss customer negative impact company business result operation failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry internationally intense company sure able attract retain quality personnel cost materially increase table content company experience difficulty delay manufacture certain product include vaccine merck past experienced difficulty manufacture certain product include vaccine example company issue product recall zerbaxa follow identification product sterility issue company future experience difficulty delay manufacture product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include supply chain delay shortage raw material change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply addition company experience difficulty delay manufacturing product cause natural disaster hurricane manufacturing difficulty result product shortage lead lose sale reputational harm company company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market affect ability realize continued growth increase company risk exposure addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect company business china grow rapidly past year importance china company overall pharmaceutical vaccine business outside increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control note competition health care environment pricing pressure china increase chinese government take step reduce cost include implement health care reform lead acceleration generic substitution available mechanism drug add nrdl evolve inclusion require price negotiation impact outlook market select brand drug add nrdl average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution government vbp program government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward addition company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk time macroeconomic growth select emerge market expect outpace europe lead significant increase health care spending country access innovative medicine patient failure maintain company presence emerge market material adverse effect company business cash flow result operation financial condition prospect table content company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter business development transaction borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate inflation negatively affect company business cash flow result operation financial condition prospect order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful certain company interest rate derivative investment base london interbank offer rate libor portion merck indebtedness bear interest variable interest rate primarily base libor libor subject recent national international regulatory guidance proposal reform cause libor cease exist entirely future company begin implement alternative reference rate alternative libor company predict consequence time additional unexpected development include increase interest expense require amendment contract reference libor pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance thirdparty relationship outsource arrangement materially adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company thirdparty service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business negative event animal health industry material adverse effect future result operation financial condition future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal african swine fever lead widespread death precautionary destruction reduce consumption demand animal adversely affect company result operation outbreak highly contagious disease near company main production site require company immediately halt manufacture animal health product site force company incur substantial expense procure raw material product risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event addition sale bravecto represent significant portion company animal health segment sale negative event respect bravecto material adverse effect company animal health sale animal health segment company business significant impact event future result operation significant table content biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition successful development testing manufacturing commercialization biologic vaccine particularly human animal health vaccine long complex expensive uncertain process unique risk uncertaintie relate biologic vaccine include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic vaccine subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval generally require release manufacture commercial human vaccine lot manufacture biologic vaccine especially large quantity complex require use innovative technology handle living microorganism lot approve biologic vaccine undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic vaccine frequently costly manufacture production ingredient derive live animal plant material biologic vaccine synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead variability manufacturing process lead allegation harm include infection allergic reaction allegation review standard investigation process lead closure product facility possible contamination event result substantial cost risk relate government regulation legal proceeding health care industry continue subject increase regulation political action discuss competition health care environment company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider executive branch congress state legislature center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs december cms issue final rule make significant change requirement effective january final rule change way manufacturer calculate good price relation certain patient support program include coupon phrma pharmaceutical industry trade group company member file complaint challenge rule invalid assert conflict plain language medicaid drug rebate statute legal table content challenge fail impact provision final rule adversely impact company business cash flow result operation financial condition prospect congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin possible manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck future drug high medicaid utilization rebate exposure amp biden administration congress continue discuss legislation design control health care cost include cost drug company predict additional future change health care industry general pharmaceutical industry particular occur change material adverse effect company business cash flow result operations financial condition prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority include fda foreign regulatory authority include japan china fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time resource necessary develop new product bring market regulation outside primarily focus drug safety effectiveness case reduction cost drug fda foreign regulatory authority include japan china substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent selling product jurisdiction company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval decrease demand company product include follow result postapproval phase trial study rereview product market recall loss marketing approval product market change government standard public expectation safety efficacy quality labeling change scrutiny advertising promotion withdrawal indication grant pursuant accelerate approval past clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling table content market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pmda chinas nmpa increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity addition dissemination promotional material evolve digital channel serve increase visibility scrutiny marketplace company subject variety international law regulation company currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business cash flow result operation financial condition prospect company law regulation include additional health care reform initiative country include additional mandatory discount fee foreign corrupt practice act antibribery corruption law iii new law regulation judicial governmental decision affect pricing drug reimbursement access marketing jurisdiction change intellectual property law change accounting standard new increase datum privacy regulation enforcement particularly china vii legislative mandate preference local manufacturing pharmaceutical vaccine product viii emerge new global regulatory requirement report payment value transfer health care professional environmental regulation potential impact importation restriction embargo trade sanction legislative andor regulatory change company subject evolve complex tax law result additional liability affect result operation financial condition company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return routinely examine tax authority connection organization economic cooperation development oecd base erosion profit shift project company require disclose information tax authority operation world lead great audit scrutiny profit earn country company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company negatively affect change tax law new tax law affect example tax rate andor revise tax law interpretation domestic foreign jurisdiction include potential change exist tax law current presidential administration congress change tax law result implementation oecd twopillar solution reform international tax landscape company take position base opinion tax counsel distribution organon common stock connection spinoff organon qualify transaction taxfree federal income tax purpose fact assumption representation undertaking company organon past future conduct respective business matter table content incorrect satisfied spinoff qualify taxfree treatment result significant federal income tax liability company shareholder adverse outcome current future legal matter negatively affect merck business current future litigation claim proceeding government investigation preclude delay commercialization merck product adversely affect merck business result operation cash flow prospect financial condition legal matter include limited intellectual property dispute adverse decision litigation include product safety liability consumer protection commercial case iii antibribery regulation foreign corrupt practice act include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant product pricing promotional matter lawsuit claim administrative proceeding assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation vii environmental health safety sustainability matter include regulatory action response climate change viii tax liability result assessment tax authority item financial statement supplementary datum note contingency environmental liability information company legal matter merck inform department health human service health resource services administration hhs merck implement update section program integrity initiative pursuant merck require hospital cover entity provide claim datum claim originate contract pharmacy entity decline submit claim datum merck new initiative provide long voluntarily honor discount chargeback contract pharmacy transaction single contract pharmacy hospital cover entitys choice hhs send letter numerous drug manufacturer state determined manufacturer action restrict contract pharmacy transaction violation statute state manufacturer cease restriction hhs seek repayment overcharge civil monetary penalty manufacturer litigation government seek confirm legality restriction merck receive similar letter hhs hhs seek implement administrative proceeding recover overcharge andor impose civil monetary penalty merck proceeding implement merck negative outcome material adverse effect merck business result operation cash flow prospect financial condition product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost insurance increase significantly company subject substantial number product liability claim item financial statement supplementary datum note contingency environmental liability information company current product liability litigation respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise risk relate technology company increasingly dependent sophisticated software application compute infrastructure company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation company target future cyberattack company increasingly dependent sophisticated software application complex information technology system compute infrastructure cloud service provider collectively system conduct table content critical operation certain system manage host provide party assist conduct company business disruption degradation manipulation system intentional accidental mean company employee party authorize access unauthorized party adversely affect key business process cyberattack company system thirdparty provider system cloudbase system result exposure confidential information modification critical datum andor failure critical operation misuse system result disclosure sensitive personal information theft trade secret intellectual property confidential business information company continue leverage new innovative technology enterprise improve efficacy efficiency business process include datum acquisition use create new risk company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation result loss company implement variety measure enhance modernize system guard similar attack future pursue enterprisewide effort enhance company resiliency future cyberattack include incident similar attack objective effort protect future cyberattack improve speed company recovery attack enable continued business operation great extent possible recovery period aggregate impact cyberattack network disruption include cyberattack company operation financial condition material date company continue target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system effort thirdparty provider protect system successful prevent disruption companys operation include manufacture research sale operation disruption past future result loss revenue loss critical sensitive information company company thirdparty provider database system past future result financial legal business reputational harm company substantial remediation cost social medium mobile messaging platform present risk challenge inappropriate andor unauthorized use certain social medium mobile message channel cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company product social networking platform damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium mobile message policy guide employee appropriate personal professional use platform communication company process place completely secure protect information identify new point entry new communication tool expand present new challenge cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative include table content statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level price pressure abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general impact global covid pandemic future pandemic epidemic similar public health threat company business operation financial performance change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product cyberattack company thirdparty provider information technology system disrupt company operation lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include china legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company table content economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter currently locate kenilworth new jersey company previously announce intend consolidate new jersey campuse single corporate headquarters location rahway new jersey end company maintain operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal research facility locate rahway kenilworth new jersey west point pennsylvania boston cambridge massachusetts south san francisco california elkhorn nebraska animal health principal research facility outside locate united kingdom switzerland china mercks manufacturing operation currently headquarter whitehouse station new jersey company production facility human health product seven location puerto rico outside subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia number property transfer organon spinoff capital expenditure billion billion billion amount billion billion billion abroad expenditure amount billion billion billion company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain company believe plant manufacture product suitable intend purpose capacity project capacity include previously disclose capital expansion project adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer person age office business experience robert davis chief executive officer president july executive vice president global services chief financial officer april sanat chattopadhyay executive vice president president merck manufacturing division march richard deluca executive vice president president merck animal health september cristal downing executive vice president chief communication public affair officer august vice president medical devices global communication public affairs johnson johnson december august vice president financial communication johnson johnson january december prior senior director communications johnson johnson kenneth frazi executive chairman july prior chairman president chief executive officer julie gerberde executive vice president chief patient officer population health sustainability july rita karachun senior vice president finance global controller march michael klobuchar executive vice president chief strategy officer july senior vice president cfo merck head global portfolio alliance management january june senior vice president corporate strategy plan president emerge business december january prior vice president global business financial planning lisa lecointecephas senior vice president chief ethic compliance officer april executive director head global investigation february april prior senior counsel litigation government investigation bristolmyers squibb company dean president merck research laboratory january senior vice president discovery sciences translational medicine merck research laboratory november january vice president translational medicine march november prior chief scientific officer associate vice president university utah health sciences caroline litchfield executive vice president chief financial officer april senior vice president corporate treasurer january march prior senior vice president global human health steven mizell executive vice president chief human resource officer december david williams executive vice president chief information digital officer august act chief information digital officer december august vice president chief information officer merck animal health december prior associate vice president chief information officer merck animal health jennifer zachary executive vice president general counsel corporate secretary january executive vice president general counsel april january prior partner covington burling llp table content february company announce arpa garay lead human health global marketing jannie oosthuizen lead human health garay oosthuizen executive officer company effective february age office business experience arpa garay president global oncology digital january president global pharmaceuticals commercial analytic digital marketing march january senior vice president vaccines business unit june march prior manage director msd norway jannie oosthuizen senior vice president president merck human health january senior vice president head global oncology commercial january december senior vice president president msd july december table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk january approximately shareholder record company common stock issuer purchase equity security month end december follow issuer purchase equity security millions total number share purchase total number average price publicly approximate dollar value share share pay announce plan purchase period purchase share program plan programs october october november november december december total share purchase period plan approve board director october purchase billion merck share treasury table content performance graph follow graph assume investment december reinvestment dividend companys common stock index composite peer group major europeanbase pharmaceutical company abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis pfizer inc roche holding sanofi comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer group merck peer group compound annual growth rate peer group average calculate market cap weight basis december performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter spinoff organon june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify treat taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note consolidated financial statement table content overview financial highlight change change exclude foreign exclude foreign million change exchange change exchange sale net income continue operation attributable merck inc gaap nongaap earning common share assume dilution continue operation attributable merck inc common shareholder gaap nongaap calculation meaningful nongaap net income nongaap earning share eps exclude acquisition divestiturerelate cost restructure cost certain item discussion reconciliation gaap nongaap net income eps nongaap income nongaap eps executive summary merck deliver strategic priority executing commercially drive strong revenue earning growth year complete key business development transaction accelerate broad pipeline achieve notable regulatory milestone june merck complete spinoff organon historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff worldwide sale billion increase compare exclude favorable effect foreign exchange sale increase drive primarily growth oncology vaccine hospital acute care animal health additionally revenue reflect benefit sale molnupiravir investigational oral antiviral covid treatment discuss covidrelated disruption negatively affect sale less extent benefit yearoveryear sale growth merck continue execute scientifically compelling business development opportunitie augment pipeline november merck acquire acceleron pharma inc acceleron publicly trade biopharmaceutical company evaluate transform growth factor tgfbeta superfamily protein development pulmonary hematologic therapie april merck acquire pandion therapeutics inc pandion clinicalstage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease additionally merck enter collaboration gilead sciences inc gilead jointly develop commercialize longacting treatment hiv merck receive approval file new drug application ndas supplemental biologic license application bla japan china company receive numerous regulatory approval oncology keytruda receive approval additional indication andor internationally monotherapy therapeutic area breast colorectal cutaneous squamous cell esophageal melanoma renal cell cancer combination chemotherapy therapeutic area breast cervical gastric gastroesophageal junction cancer keytruda approve combination lenvima treatment certain adult patient endometrial cancer treatment renal cell cancer lenvima develop collaboration eisai ltd eisai lynparza develop collaboration astrazeneca plc astrazeneca receive approval china monotherapy treatment certain adult patient metastatic castration resistant prostate cancer additionally food drug administration fda approve welireg belzutifan oral hypoxiainducible factor alpha hif inhibitor treatment adult patient von hippellindau vhl table content disease require therapy associate renal cell carcinoma rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumor require immediate surgery update february fda grant emergency use authorization eua molnupiravir investigational oral antiviral covid treatment develop collaboration ridgeback biotherapuetic ridgeback molnupiravir receive conditional marketing authorization united kingdom special approval emergency japan fda european commission approve vaxneuvance pneumococcal valent conjugate vaccine pneumococcal conjugate vaccine use adult additionally verquvo medicine reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult approve japan verquvo jointly develop bayer bayer january japan ministry health labor welfare mhlw approve lyfnua gefapixant adult refractory unexplained chronic cough addition recent regulatory approval discuss company advanced latestage pipeline regulatory submission keytruda review andor internationally supplemental indication treatment certain patient triple negative breast cervical endometrial melanoma renal cell tumor mutation burdenhigh tmbh cancer lynparza review supplemental indication treatment certain patient breast prostate cancer lenvima review combination keytruda supplemental indication treatment certain patient hepatocellular carcinoma hcc molnupiravir roll review european medicine agency ema gefapixant selective nonnarcotic orallyadministere investigational pxreceptor antagonist develop treatment refractory chronic cough review vaxneuvance valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease pediatric patient review japan use adult company phase oncology program include keytruda therapeutic area biliary cutaneous squamous cell gastric hepatocellular mesothelioma ovarian prostate smallcell lung cancer lynparza monotherapy colorectal cancer combination keytruda nonsmallcell lung smallcell lung cancer lenvima combination keytruda colorectal esophageal gastric head neck melanoma nonsmallcell lung cancer welireg rcc mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab rcc pembrolizumab subcutaneous nonsmallcell lung cancer nsclc tukysa tucatinib develop collaboration seagen inc seagen breast cancer mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab colorectal cancer mka coformulation vibostolimab antitigit therapy pembrolizumab nsclc additionally company candidate phase clinical development therapeutic area include sotatercept treatment pulmonary arterial hypertension pah obtain acceleron acquisition clesrovimab prevention respiratory syncytial virus islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti prevention hiv infection clinical hold table content mka islatravir combination doravirine treatment hiv infection clinical hold molnupiravir reflect phase development remain investigational follow eua company allocate resource support commercial opportunity near term invest heavily research support future innovation longterm growth research development expense reflect high clinical development spending increase investment discovery research early drug development november mercks board director approve increase company quarterly dividend raising share share company outstanding common stock company return billion shareholder dividend share repurchase december company complete inaugural issuance billion sustainability bond billion underwritten bond offer company intend use net proceed sustainability bond offer support project partnership company priority environmental social governance esg area contribute advancement united nations sustainable development goal covid update covid pandemic merck remain focused protect safety employee ensure supply medicine vaccine reach patient contribute scientific expertise development antiviral therapy support effort expand manufacturing capacity supply sarscovcovid medicine vaccine support health care provider merck community covidrelated disruption negatively affect result merck continue experience strong global underlying demand business merck sale unfavorably affect covidrelated disruption result estimate negative impact merck pharmaceutical segment sale approximately billion roughly merck pharmaceutical segment revenue comprise physicianadministered product despite strong underlie demand affect social distancing measure few visit merck sale favorably affect authorization molnupiravir market discuss result sale million estimate negative impact covidrelate disruption merck sale approximately billion approximately billion attributable pharmaceutical segment approximately million attributable animal health segment april merck announce discontinuing development know cdfc treatment hospitalize patient covid obtain merck acquisition oncoimmune note consolidated financial statement decision result charge million cost sale january company announce discontinuation development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccine discontinuation company record charge million million reflect cost sale remain million cost reflect research development expense operating expense reflect minor positive effect investment covidrelate research largely offset favorable impact low spending area covid pandemic operating expense positively affect approximately million primarily lower promotional selling cost low research development expense net investment covidrelate antiviral vaccine research program addition covid pandemic cause disruption volatility company global supply chain network company future experience disruption availability delay shipment raw material packaging relate cost inflation december fda grant eua molnupiravir base positive result phase moveout clinical trial additionally december japans mhlw grant special approval table content emergency molnupiravir november medicines healthcare product regulatory agency grant conditional marketing authorization molnupiravir addition october ema initiate rolling review molnupiravir merck plan work committee medicinal product human use ema complete rolling review process facilitate initiate formal review marketing authorization application merck develop molnupiravir collaboration ridgeback company actively work regulatory agency worldwide submit application emergency use marketing authorization merck enter advance purchase supply agreement molnupiravir market note consolidated financial statement additional information relate collaboration ridgeback march merck announce enter multiple agreement support effort expand manufacturing capacity supply sarscov covid medicine vaccine biomedical advanced research development authority barda division office assistant secretary preparedness response department health human service provide merck funding adapt available number exist manufacturing facility production sarscovcovid vaccine medicines merck enter agreement support manufacture supply johnson johnsons sarscovcovid vaccine merck certain facility produce drug substance formulate fill vial johnson johnsons vaccine price global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform enact prior year increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government party low health care cost biden administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future continue negatively affect revenue performance operating result sale change change exclude foreign exclude foreign million change exchange change exchange united states international total worldwide sale grow primarily high sale oncology franchise largely drive strong growth keytruda increase alliance revenue lynparza lenvima high sale vaccine franchise primarily attributable growth gardasilgardasil varivax proquad contribute revenue growth high sale virology franchise attributable molnupiravir high sale hospital acute care franchise reflect growth bridion prevymis high sale animal health product additionally sale benefit high party manufacturing sale achievement milestone outlicense product trigger contingent payment merck discuss covidrelated disruption unfavorably affect sale less extent benefit yearoveryear sale growth sale growth partially offset low sale pneumovax suspension sale hospital acute care product zerbaxa low sale virology product isentressisentress sale grow primarily drive high sale keytruda sale molnupiravir high sale bridion gardasil varivax proquad increase alliance revenue lynparza lenvima table content high sale animal health product low sale pneumovax januviajanumet zerbaxa partially offset revenue growth international sale increase primarily growth gardasilgardasil keytruda sale molnupiravir increase alliance revenue lynparza lenvima high sale januviajanumet bridion prevymis animal health product international sale growth partially offset low sale noxafil zerbaxa isentressisentress international sale represent total sale respectively worldwide sale increase primarily high sale oncology franchise growth certain hospital acute care product animal health growth area largely offset negative effect covid pandemic discuss competitive pressure virology franchise pricing pressure diabete franchise note consolidated financial statement detail sale company product discussion performance select product franchise follow pharmaceutical segment oncology change exclude change foreign exclude foreign million change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima emend alliance revenue represent merck share profit product sale net cost sale commercialization cost note consolidated financial statement keytruda antipd program death receptor therapy approve monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hcc nsclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer solid tumor include msihdmmr colorectal cancer primary mediastinal large bcell lymphoma tmbh cancer solid tumor urothelial carcinoma include nonmuscle invasive bladder cancer additionally keytruda approve monotherapy adjuvant treatment certain patient rcc keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy bevacizumab cervical cancer combination chemotherapy esophageal cancer combination chemotherapy gastric cancer combination chemotherapy hnscc combination chemotherapy triplenegativebreast cancer tnbc combination axitinib advance rcc combination lenvima endometrial carcinoma rcc keytruda clinical development program include study broad range cancer type global sale keytruda grew drive high demand company continue launch keytruda multiple new indication globally covid pandemic dampen effect grow demand negatively affect number new patient start treatment sale continue build multiple approve indication particular treatment advanced nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc continue uptake tnbc rcc hnscc msih cancer esophageal cancer indication keytruda sale growth international market reflect continue uptake predominately nsclc hnscc rcc indication particularly europe sale growth partially offset low pricing europe china japan global sales keytruda grew drive high demand globally particularly europe covid pandemic unfavorable effect grow demand sale growth partially offset low pricing japan europe table content keytruda receive numerous regulatory approval summarize date approval january approval firstline treatment adult patient msih dmmr colorectal cancer base keynote study approval expand label monotherapy treatment adult pediatric patient age year old relapse march refractory chl fail autologous stem cell transplant asct follow prior therapy asct treatment option base keynote keynote trial fda approval combination platinum fluoropyrimidinebase chemotherapy treatment certain patient locally advanced march metastatic esophageal gej carcinoma amenable surgical resection definitive chemoradiation base keynote trial fda approval combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy firstline treatment patient locally advance unresectable metastatic human epidermal growth factor receptor herpositive gastric gej adenocarcinoma base keynote trial approval week dose regimen indication keytruda administer combination anticancer agent china national medical products administration nmpa approval firstline treatment adult patient msih dmmr colorectal june cancer kras nras braf wildtype base keynote study approval combination chemotherapy firstline treatment patient locally advance unresectable metastatic carcinoma june esophagus hernegative gej adenocarcinoma adult tumor express pdl base keynote trial fda approval monotherapy treatment patient locally advanced cscc curable surgery radiation base july keynote trial fda approval keytruda plus lenvima treatment patient advance endometrial carcinoma msih dmmr july disease progression follow prior systemic therapy set candidate curative surgery radiation base keynotestudy trial fda approval keytruda treatment patient highrisk earlystage tnbc combination chemotherapy neoadjuvant treatment july continue single agent adjuvant treatment surgery base keynote trial fda approval keytruda plus lenvima firstline treatment adult patient advance rcc base keynote trialstudy august trial japans pharmaceuticals medical devices agency pmda approval treatment patient unresectable advanced recurrent august msih colorectal cancer base keynote trial japans pmda approval treatment patient pdlpositive hormone receptornegative hernegative inoperable recurrent august breast cancer base keynote trial chinas nmpa approval combination chemotherapy firstline treatment patient locally advance unresectable september metastatic carcinoma esophagus gej base keynote trial fda approval combination chemotherapy bevacizumab treatment patient persistent recurrent october metastatic cervical cancer base keynote trial approval combination chemotherapy firstline treatment locally recurrent unresectable metastatic tnbc adult october tumor express pdl receive prior chemotherapy metastatic disease base keynote trial fda approval adjuvant treatment patient rcc intermediatehigh high risk recurrence follow nephrectomy follow november nephrectomy resection metastatic lesion base keynote trial table content approval keytruda plus lenvima firstline treatment adult patient advance rcc base clear study november keynote trial approval keytruda plus lenvima treatment advanced recurrent endometrial carcinoma adult disease progression november follow prior treatment platinumcontaine therapy set candidate curative surgery radiation base keynotestudy trial japans pmda approval combination chemotherapy fluorouracil plus cisplatin firstline treatment patient radically november unresectable advanced recurrent esophageal carcinoma combination chemotherapy base keynote trial fda approval adjuvant treatment adult pediatric year old patient stage iib iic melanoma follow complete december resection base keynote trial fda expand indication adjuvant treatment stage iii melanoma follow complete resection include pediatric patient year old japans mhlw approval keytruda combination lenvima treatment patient unresectable advanced recurrent december endometrial carcinoma progress cancer chemotherapy base keynotestudy trial march merck announce voluntarily withdraw indication keytruda treatment patient metastatic smallcell lung cancer disease progression platinumbase chemotherapy prior line therapy withdrawal indication consultation fda affect indication keytruda announce january keynote confirmatory phase trial indication meet dual primary endpoint progressionfree survival reach statistical significance primary endpoint overall survival merck initiate withdrawal accelerate approval indication keytruda treatment patient recurrent locally advanced metastatic gastric gej adenocarcinoma tumor express pdl disease progression prior line therapy decision consultation fda follow oncologic drug advisory committee evaluation thirdline gastric cancer indication keytruda monotherapy fail meet postmarkete requirement demonstrate overall survival benefit phase study withdrawal indication affect indication keytruda company party certain thirdparty license agreement pursuant company pay royalty sale keytruda term significant agreement merck pay royalty worldwide sale keytruda party royalty decline terminate company pay additional royalty worldwide sale keytruda party termination date vary country royalty expire major european market royalty include cost sale lynparza oral poly adpribose polymerase parp inhibitor develop collaboration astrazeneca note consolidated financial statement lynparza approve treatment certain type advance ovarian breast pancreatic prostate cancer alliance revenue relate lynparza grow continued uptake multiple approve indication europe japan china june lynparza grant conditional approval china monotherapy treatment certain previously treat adult patient germline somatic brcamutate metastatic castrationresistant prostate cancer base result profound trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai note consolidated financial statement lenvima approve treatment certain type thyroid cancer hcc combination everolimus certain patient rcc combination keytruda treatment certain patient endometrial carcinoma treatment certain patient rcc alliance revenue relate lenvima grow primarily high demand china global sales emend aprepitant prevention certain chemotherapyinduced nausea vomiting decline reflect low volume europe china worldwide sale emend table content decrease primarily low demand price generic competition emend injection follow patent expiry september contribute emend sale decline low demand europe japan result generic competition oral formulation emend follow loss market exclusivity december respectively june koselugo selumetinib grant conditional approval treatment pediatric patient year age old neurofibromatosis type symptomatic inoperable plexiform neurofibromas base positive result national cancer institute cancer therapy evaluation programsponsore sprint stratum trial koselugo approve fda april koselugo collaboration astrazeneca reference include lynparza august fda approve welireg oral hif inhibitor treatment adult patient vhl disease require therapy associate rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumor require immediate surgery approval base result openlabel study trial welireg obtain merck acquisition peloton therapeutics inc peloton note consolidated financial statement vaccine change exclude change foreign exclude foreign million change exchange change exchange gardasilgardasil proquad mmr varivax pneumovax worldwide sale gardasilgardasil vaccine help prevent certain cancer disease cause certain type human papillomavirus hpv grew drive primarily strong global demand particularly china increase supply high pricing china contribute sale growth sale growth unfavorably affect replenishment dose borrow center disease control prevention cdc pediatric vaccine stockpile favorably affect sale million time public sector purchase partially offset sale growth global sale gardasilgardasil grow primarily high volume china replenishment dose borrow cdc pediatric vaccine stockpile replenishment result recognition sale million combine reduction sale million borrowing result favorable impact sale million compare low demand hong kong sar prc attributable covid pandemic partially offset increase sale gardasilgardasil company party certain thirdparty license agreement pursuant company pay royalty sale gardasilgardasil term significant agreement merck pay royalty worldwide sale gardasilgardasil party royalty obligation agreement expire december additional royalty sale gardasilgardasil party royalty obligation expire december royalty include cost sale global sale proquad pediatric combination vaccine help protect measle mump rubella varicella grow high sale reflect high demand drive ongoing covid pandemic recovery high pricing worldwide sale proquad decline drive primarily low demand result few measle outbreak compare couple unfavorable impact covid pandemic partially offset high pricing worldwide sale mmr vaccine help protect measle mump rubella grow primarily high sale reflect ongoing covid pandemic recovery inclusive high public sector mix business low demand europe partially offset mmr sale growth global sale mmr decline drive primarily low demand result few table content measle outbreak compare couple unfavorable impact covid pandemic low demand brazil contribute sale decline global sale varivax vaccine help prevent chickenpox varicella grew primarily reflect ongoing covid pandemic recovery high pricing high government tender brazil contribute varivax sale growth worldwide sale varivax decline drive primarily low demand result covid pandemic partially offset high pricing varivax sale decline attributable low government tender brazil worldwide sale pneumovax vaccine help prevent pneumococcal disease decline primarily low sale attributable low demand reflect prioritization covid vaccination partially offset high pricing global sale pneumovax grow primarily high volume europe attributable heighten awareness pneumococcal vaccination high pricing contribute pneumovax sale growth july fda approve vaxneuvance active immunization prevention invasive disease cause streptococcus pneumoniae serotype adult year age old december vaxneuvance approve approval base datum seven clinical study assess safety tolerability immunogenicity adult october cdcs advisory committee immunization practice acip vote recommend vaccination sequential regimen vaxneuvance follow pneumovax single dose valent pneumococcal conjugate vaccine adult year old adult age certain underlie medical condition recommendation subsequently adopt director cdc department health human service publish cdcs morbidity mortality weekly report september merck announce settlement license agreement pfizer inc pfizer resolve worldwide patent infringement litigation relate use merck investigational license pneumococcal conjugate vaccine pcv product include vaxneuvance term agreement merck certain regulatory milestone payment pfizer royalty payment worldwide sale pcv product company pay royalty net sale merck pcv product net sale merck pcv product vaxeli diphtheria tetanus toxoid acellular pertussis inactivate poliovirus haemophilus conjugate hepatitis vaccine develop usbased partnership merck sanofi pasteur available active immunization child week year age help prevent diphtheria tetanus pertussis poliomyelitis hepatitis invasive disease haemophilus influenzae type february cdcs acip include vaxeli combination vaccine option cdcs recommend child adolescent immunization schedule sale vaxeli usbased mercksanofi pasteur partnership result reflect equity income affiliate include income expense net supply sale partnership record sale vaxeli approve market directly merck sanofi pasteur hospital acute care change change exclude foreign exclude foreign million change exchange change exchange bridion prevymis noxafil zerbaxa calculation meaningful global sale bridion reversal type neuromuscular block agent surgery grow high demand globally particularly europe attributable covid pandemic recovery increase usage neuromuscular blockade reversal agent bridion grow share class bridion approve fda june pediatric patient age year old undergo surgery worldwide sale bridion grow high demand globally table content particularly few elective surgery result covid pandemic unfavorably affect demand worldwide sale prevymis medicine prophylaxis prevention cytomegalovirus cmv infection disease adult cmvseropositive recipient allogenic hematopoietic stem cell transplant grew increase continue uptake launch market particularly europe worldwide sales noxafil antifungal agent prevention certain invasive fungal infection decline primarily generic competition europe partially offset high demand china patent provide market exclusivity noxafil number major european market expire december result company experience low demand noxafil market generic competition expect decline continue global sale noxafil decline generic competition europe patent provide market exclusivity certain form noxafil represent majority noxafil sale expire july december company temporarily suspend sale zerbaxa combination antibacterial betalactamase inhibitor treatment certain bacterial infection subsequently issue product recall follow identification product sterility issue result company record intangible asset impairment charge relate zerbaxa note consolidated financial statement phase resupply zerbaxa initiate fourth quarter company expect continue immunology change change exclude foreign exclude foreign million change exchange change exchange simponi remicade sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey decline nearly flat sale simponi unfavorably affect biosimilar competition compete product company expect competition continue unfavorably affect sale simponi sale remicade treatment inflammatory disease market company europe russia turkey declined decrease drive ongoing biosimilar competition company marketing territory europe company lose market exclusivity remicade major european market long market exclusivity marketing territory company experience pricing volume decline market result biosimilar competition expect decline continue company marketing right respect product revert janssen pharmaceuticals inc october virology change exclude change foreign exclude foreign million change exchange change exchange molnupiravir isentressisentress zepati molnupiravir investigational oral antiviral covid medicine develop collaboration ridgeback note consolidated financial statement fda grant eua molnupiravir december update february authorize molnupiravir treatment mild moderate covid highrisk adult alternative fdaapprove authorize treatment option table content accessible clinically appropriate december japans mhlw grant special approval emergency molnupiravir treat infectious disease cause sarscov november uks mhra grant conditional marketing authorization molnupiravir treat mild moderate covid adult risk develop severe illness merck enter advance purchase supply agreement molnupiravir market merck begin ship molnupiravir fourth quarter country approve authorize sale molnupiravir million primarily consist sale japan worldwide sale isentressisentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection decline decrease primarily competitive pressure particularly europe company expect competitive pressure isentressisentress continue global sale zepati treatment adult patient chronic hepatitis virus genotype infection decline primarily low demand competitive pressure europe worldwide sale zepatier decline drive low demand globally competition decline patient volume couple impact covid pandemic cardiovascular change exclude change foreign exclude foreign million change exchange change exchange alliance revenue adempasverquvo adempas alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note consolidated financial statement adempas verquvo worldwide collaboration bayer market develop soluble guanylate cyclase sgc modulator note consolidated financial statement adempas approve treatment certain type pah verquvo approve january reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult symptomatic chronic heart failure reduce ejection fraction verquvo approve japan june july approval base result victoria trial alliance revenue collaboration grow rise revenue collaboration include sale adempas verquvo merck marketing territory sale adempas merck marketing territory grew primarily reflect high demand europe diabetes change change exclude foreign exclude foreign million change exchange change exchange januviajanumet worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete nearly flat decline sale performance period reflect continue pricing pressure low demand largely offset high demand certain international market particularly china company expect pricing pressure continue januvia janumet lose market exclusivity january september china july company anticipate sale januvia janumet market decline substantially loss exclusivity combine sale januvia janumet europe china represent respectively total combine januvia janumet sale table content animal health segment change change exclude foreign exclude foreign million change exchange change exchange livestock companion animal sale livestock product grow primarily high demand ruminant product include animal health intelligence solution animal identification monitor traceability high demand poultry swine product sale livestock product increase predominantly additional month sale relate april acquisition antelliq leader digital animal identification traceability monitoring solution note consolidated financial statement sale companion animal product grow rise primarily high demand parasiticide include bravecto line product high demand companion animal vaccine cost expense million change change cost sale sell general administrative research development restructuring cost income expense net calculation meaningful cost sale cost sale billion billion cost sale include amortization intangible asset record connection acquisition collaboration license arrangement total billion billion billion cost include charge million million respectively relate discontinuation covid development program note consolidated financial statement additionally cost include intangible asset impairment charge billion million relate market product intangible note consolidated financial statement company recognize additional impairment charge future relate intangible asset measure fair value capitalize connection business combination charge material cost include inventory writeoff million relate recall zerbaxa note consolidated financial statement include cost sale expense associate restructuring activity amount million million million primarily reflect accelerated depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare gross margin improvement reflect low impairment amortization intangible asset note favorable effect product mix low inventory writeoff partially offset gross margin improvement high manufacturing cost impact molnupiravir low gross margin profit sharing ridgeback discuss note consolidated financial statement high compensation benefit cost gross margin compare gross margin decline reflect unfavorable effect high impairment amortization intangible asset pricing pressure charge relate discontinuation covid vaccine development program high inventory writeoff relate recall zerbaxa note partially offset favorable effect product mix low restructuring cost table content sell general administrative selling general administrative sga expense billion increase compare increase primarily high administrative cost include compensation benefit high promotional expense support company key growth pillar high acquisitionrelate cost include cost relate acquisition acceleron covid pandemic drive low spending contribute increase sga expense increase partially offset favorable effect foreign exchange contribution merck foundation sga expense billion decline compare decline drive primarily low administrative sell promotional cost include low travel meeting expense covid pandemic favorable effect foreign exchange partially offset contribution merck foundation research development research development expense billion decline compare primarily lower upfront payment relate acquisition collaboration decline partially offset high clinical development spending increase investment discovery research early drug development net reimbursement portion molnupiravir development cost partnership ridgeback high compensation benefit cost high inprocess research development iprd impairment charge cost relate acquisition acceleron partially offset decline expense expense billion increase compare increase drive largely higher upfront payment relate acquisition collaboration high clinical development spending increase investment discovery research early drug development high restructuring cost contribute increase expense increase expense partially offset low iprd impairment charge low cost result covid pandemic net spending covidrelate vaccine antiviral research program expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity billion billion billion include expense animal health research cost license cost cost incur division support activity include depreciation production general administrative aggregate billion billion billion additionally expense include billion charge acquisition pandion expense include billion charge acquisition velosbio inc million charge acquisition oncoimmune charge million relate transaction seagen expense include million charge acquisition peloton note consolidated financial statement information transaction expense include iprd impairment charge million million million respectively note consolidated financial statement company recognize additional impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business combination charge material addition expense include million million respectively cost associate restructuring activity primarily relate accelerated depreciation expense include expense income relate change estimate fair value measurement liability contingent consideration record connection business combination company record million expense compare net reduction expense million million respectively relate change estimate restructure cost merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructuring program action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company expect record charge table content approximately million related restructuring program company anticipate action restructure program result annual net cost saving approximately million end restructuring cost primarily represent separation relate cost associate restructuring activity million million million separation cost incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate include restructuring cost asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include cost sale sell general administrative expense research development cost company record aggregate pretax cost million million million related restructuring program activity note consolidated financial statement income expense net income expense net billion income compare million income primarily high income investment equity security net largely related higher realize unrealized gain certain investment include disposition company ownership interest preventice solutions inc preventice result acquisition preventice boston scientific partially offset high foreign exchange loss pension settlement cost income expense net million income compare million expense primarily high income investment equity security net largely related moderna inc detail component income expense net note consolidated financial statement segment profit million pharmaceutical segment profit animal health segment profit nonreportable segment profit income continue operation taxis pharmaceutical segment profit comprise segment sale standard cost sga expense directly incur segment animal health segment profit comprise segment sale cost sale sga expense directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe expense incur mrl general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit cost related restructuring activity acquisition divestiturerelated cost include amortization intangible asset amortization purchase accounting adjustment intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacturing sale begin amortization intangible asset previously include calculation table content segment profit include unallocated nonsegment corporate expense prior period pharmaceutical animal health segment profit recast reflect change comparable basis pharmaceutical segment profit grow primarily high sale favorable effect foreign exchange partially offset high administrative promotional cost pharmaceutical segment profit increase drive primarily high sale lower sell promotional cost animal health segment profit grew reflect high sale partially offset high promotional sell administrative cost animal health segment profit increase drive primarily high sale low promotional selling cost partially offset high cost unfavorable effect foreign exchange taxis income effective income tax rate continue operation year effective income tax rate reflect favorable mix income expense high foreign tax credit ordinary business operation company able credit effective income tax rate continue operation reflect beneficial impact settlement foreign tax matter net tax benefit million relate settlement certain federal income tax matter note consolidated financial statement effective income tax rate continue operation reflect unfavorable effect charge acquisition pandion tax benefit recognize effective income tax rate reflect unfavorable impact charge acquisition velosbio tax benefit recognize effective income tax rate reflect favorable impact million net tax benefit relate settlement certain federal income tax matter note consolidated financial statement reversal tax reserve establish connection divestiture merck consumer care mcc business lapse statute limitation addition effective income tax rate reflect unfavorable impact charge acquisition peloton tax benefit recognize charge million relate finalization treasury regulation transition tax associate enactment tax legislation know tax cut job act tcja note consolidated financial statement net income loss attributable noncontrolle interest net income loss attributable noncontrolle interest million million million loss drive primarily portion goodwill impairment charge relate certain business healthcare service segment attributable noncontrolle interest nongaap income nongaap ep continue operation nongaap income nongaap ep alternative view company performance merck provide management believe information enhance investor understand company result permit investor understand management assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost income loss investment equity security certain item exclude item significant component understanding assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps management use measure internally plan forecasting purpose measure performance company metric addition senior management annual compensation derive nongaap pretax income nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance generally accept accounting principle gaap table content reconciliation gaap financial measure nongaap financial measure continue operation follow million share amount income continue operation taxis report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost income investment equity security net item charge acquisition pandion charge discontinuation covid development program charge acquisition velosbio charge formation collaboration charge acquisition oncoimmune charge acquisition peloton nongaap income continue operation taxis tax income report gaap estimate tax benefit exclude item net tax benefit settlement certain federal income tax matter adjustment tax benefit record conjunction cubist pharmaceuticals inc acquisition tax benefit reversal tax reserve relate divestiture mcc net tax charge relate finalization treasury regulation relate enactment tcja nongaap taxes income continue operation nongaap net income continue operation net income loss attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income continue operation attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution continue operation report gaap ep difference nongaap ep assume dilution continue operation include billion intangible asset impairment charge relate zerbaxa include million intangible asset impairment charge relate sivextro note consolidated financial statement include million relate transaction seagen note consolidated financial statement estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment acquisition divestiturerelated cost nongaap income nongaap eps exclude impact certain amount record connection acquisition divestiture amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration exclude integration transaction certain cost associate acquisition divestiture nongaap income nongaap eps exclude amortization intangible asset relate collaboration license arrangement table content restructuring cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost income loss investment equity security nongaap income nongaap eps exclude realize unrealized gain loss investment equity security own directly ownership interest investment fund certain item nongaap income nongaap eps exclude certain item item adjusted evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge acquisition pandion velosbio oncoimmune peloton charge relate collaboration include transaction seagen note consolidated financial statement exclude nongaap income nongaap eps charge relate discontinuation covid development program note consolidated financial statement additionally exclude nongaap income nongaap ep certain tax item include net tax benefit relate settlement certain federal income tax matter adjustment tax benefit record conjunction acquisition cubist pharmaceuticals inc tax benefit relate reversal tax reserve establish connection divestiture mcc net tax charge relate finalization treasury regulation relate tcja note consolidated financial statement research development research pipeline company currently candidate regulatory review internationally latestage clinical development chart reflect company current research pipeline february relate discussion set forth item business research development acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent transaction summarize additional detail include note consolidated financial statement merck actively monitor landscape growth opportunity meet company strategic criterion march merck gilead enter agreement jointly develop commercialize longacting treatment hiv combine merck investigational nrtti islatravir gilead investigational capsid inhibitor lenacapavir collaboration initially focus longacte oral formulation longacte injectable formulation combination product formulation potentially add collaboration mutually agree upfront payment party enter agreement april merck acquire pandion clinicalstage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease total consideration billion pandion advance pipeline precision immune modulator target critical immune control node november merck acquire acceleron publicly trade biopharmaceutical company total consideration billion acceleron evaluate tgfbeta superfamily protein know play central role regulation cell growth differentiation repair acceleron lead therapeutic candidate table content sotatercept novel mechanism action potential improve shortterm andor longterm clinical outcome patient pah sotatercept phase trial addon current standard care treatment pah addition sotatercept acceleron portfolio include reblozyl luspatercept firstinclass erythroid maturation recombinant fusion protein approve europe canada australia treatment anemia certain rare blood disorder evaluate clinical trial additional indication hematology therapy reblozyl develop commercialize global collaboration bristol myers squibb acquire inprocess research development connection business combination company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion note consolidated financial statement iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally iprd program require additional clinical trial datum previously anticipate program fail abandon development company realize future cash flow estimate record iprd acquisition date circumstance occur company future operating result adversely affect company recognize impairment charge material company record iprd impairment charge research development expense million million million respectively note consolidated financial statement additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval capital expenditure capital expenditure billion billion billion expenditure billion billion billion company plan invest approximately billion capital project include expand manufacturing capacity oncology vaccine animal health product depreciation expense billion billion billion billion billion billion relate location total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operating activity continue operation total debt table content increase work capital compare primarily related decrease shortterm debt cash provide operating activity continue operation billion compare billion billion high cash provide operating activity continue operation reflect strong operating performance cash provide operating activity continue operation include upfront milestone payment relate collaboration million billion million cash provide operating activity continue operation continue company source fund finance operating need excess cash serve primary source fund finance capital expenditure treasury stock purchase dividend pay shareholder cash investing activity continue operation billion compare billion high use cash investing activity continue operation primarily high cash acquisition include acquisition acceleron lower proceed sale security investment partially offset purchase seagen common stock cash investing activity continue operation billion compare billion increase drive primarily low proceed sale security investment high use cash acquisition high capital expenditure purchase seagen common stock partially offset low purchase security investment cash provide financing activity continue operation billion compare use cash financing activity continue operation billion change primarily drive cash distribution receive organon connection spinoff note consolidated financial statement high proceed issuance debt low purchase treasury stock partially offset net decrease shortterm borrowing compare net increase shortterm borrowing high payment debt high dividend pay shareholder cash financing activity continue operation billion compare billion low use cash financing activity continue operation drive primarily net increase shortterm borrowing compare net decrease shortterm borrowing low purchase treasury stock partially offset high payment debt low proceed issuance debt high dividend pay shareholder low proceed exercise stock option december company issue billion principal senior unsecured note consist billion note billion note billion note billion note billion note merck net proceed offer note note note note general corporate purpose include repayment outstanding commercial paper borrowing include commercial paper borrowing connection mercks acquisition acceleron indebtedness merck allocate equal net proceed offer note finance refinance project partnership companys priority esg area june company issue billion principal senior unsecured note consist billion note billion note billion note billion note merck net proceed offer general corporate purpose include repayment outstanding commercial paper borrowing indebtedness march company issue billion principal senior unsecured note consist million note billion note billion note billion note company net proceed offer general corporate purpose include repayment outstanding commercial paper borrowing february company billion note mature accordance term repay company billion note companys billion note mature accordance term repay company billion note million floatingrate note mature accordance term repay table content company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility company expect foreseeable liquidity capital resource requirement meet exist cash cash equivalent anticipate cash flow operation commercial paper borrowing longterm borrowing need merck believe source finance adequate meet future requirement company material cash requirement arise normal course business primarily include debt obligation interest payment note consolidated financial statement detail company debt obligation timing expect future principal interest payment tax liability connection enactment tcja company require pay onetime transition tax company elect pay period year permit tcja additionally company liability unrecognize tax benefit include interest penalty note consolidated financial statement information pertain transition tax liability unrecognize tax benefit operating lease note consolidated financial statement detail companys lease obligation timing expect future lease payment contingent milestone payment company accrue liability contingent salesbase milestone payment relate collaboration astrazeneca eisai bayer payment deem probable remain subject achievement relate sale milestone note consolidated financial statement additional information relate salesbased milestone purchase obligation purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising purchase obligation include future inventory purchase company commit connection certain divestiture december company total purchase obligation billion billion estimate payable march company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company believe maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november mercks board director increase quarterly dividend declare quarterly dividend share company outstanding common stock pay january january board director declare quarterly dividend share company common stock second quarter payable april october mercks board director authorize purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction merck restart share repurchase program company temporarily suspend march company spend million purchase million share common stock treasury program december company remain share repurchase table content authorization billion company purchase billion billion common stock respectively authorize share repurchase program financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning comprehensive income loss oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record accumulate comprehensive loss aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen british pound canadian dollar swiss franc exposure develop country currency include chinese renminbi company enter forward contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost table content hedge instrument cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income continue operation taxis decline approximately million million respectively company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fix rate note notional amount match hedge fixedrate note detailed table million number interest rate total swap notional debt instrument par value debt swap hold note note interest rate swap mature february table content interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract note consolidated financial statement discussion pende discontinuation libor reference rate reform cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting estimate companys consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition disposition determine transaction account acquisition disposal asset business company make certain judgment include assessment input process output associate acquire set activity company determine substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception fair value intangible asset determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer table content estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent relate patent term extension net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization certain company business combination involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment company determine transaction account acquisition business transaction account asset acquisition business combination goodwill record asset acquisition acquire iprd alternative future use charge expense contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward table content ownership transfer customer company entitle payment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue company continually monitor provision aggregate customer discount material adjustment estimate associate aggregate customer discount provision summarize information change aggregate customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month table content month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside payment term typically day day certain market long payment term distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide abovementioned datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense table content reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense continue operation million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weightedaverage period year segment reporting share base compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension plan total million million million net periodic benefit credit postretirement benefit plan million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation table content expect rate return plan asset change net periodic benefit cost year year pension plan attributable settlement charge incur certain plan change discount rate company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum current market condition actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare range company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount primarily reflect difference expect actual return plan asset effect change actuarial assumption record component aocl expect return pension plan base calculate marketrelated value asset net loss amount aocl excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design streamline company cost structure result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue termination cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect cost sale sell general administrative expense research development expense depend nature asset table content impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible asset exclude iprd initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize operating result judgment evaluate impairment longlive intangible materially affect company result operation tax income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax table content position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement recently issue accounting standard discussion recently issue accounting standard note consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative include statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense cost sale sell general administrative research development restructuring cost income expense net income continue operation taxis tax income continue operation net income continue operation net income loss attributable noncontrolle interest net income continue operation attributable merck inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck inc common shareholder income continue operation income discontinue operation net income consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive income loss net taxis net unrealized gain loss derivative net reclassification net unrealized loss gain investment net reclassification benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent account receivable net allowance doubtful account inventory exclude inventory classify asset note current asset current asset discontinue operation total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset noncurrent asset discontinue operation liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable current liability discontinue operation total current liability longterm debt defer income taxis noncurrent liability noncurrent liability discontinue operation merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net loss attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net taxis cash dividend declare common stock share treasury stock share purchase spinoff organon net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity continue operation net income continue operation adjustment reconcile net income continue operation net cash provide operating activity continue operation amortization depreciation intangible asset impairment charge income investment equity security net charge acquisition pandion therapeutics inc charge acquisition velosbio inc charge acquisition peloton therapeutics inc defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity continue operation cash flow invest activity continue operation capital expenditure purchase seagen inc common stock purchase security investment proceed sale security investment acquisition acceleron pharma inc net cash acquire acquisition pandion therapeutics inc net cash acquire acquisition velosbio inc net cash acquire acquisition arqule inc net cash acquire acquisition antelliq corporation net cash acquire acquisition peloton therapeutics inc net cash acquire acquisition net cash acquire net cash investing activity continue operation cash flow financing activity continue operation net change shortterm borrowing payment debt proceed issuance debt distribution organon purchase treasury stock dividend pay stockholder proceed exercise stock option net cash provide financing activity continue operation discontinue operation net cash provide operating activity net cash investing activity net cash financing activity net cash flow provide discontinued operation effect exchange rate change cash cash equivalent restrict cash net increase decrease cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year includes restrict cash january include asset note cash cash equivalent relate discontinued operation cash cash equivalent restrict cash end year includes restrict cash december include asset note accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter spinoff organon june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify treat taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value table content define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record asset acquisition acquire inprocess research development iprd alternative future use charge expense contingent consideration recognize acquisition date foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive loss aocl reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost net realizable value cost substantial majority pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt security classify availableforsale report fair value fair value company investment marketable debt security determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value impairment relate report net taxis comprehensive income oci company consider available evidence evaluate potential impairment investment marketable debt security include extent fair value cost allowance credit loss require adverse factor affect value security impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis impairment recognize earning record income expense net limited portion attribute credit loss remain portion impairment relate factor recognize oci realize gain loss debt security include income expense net investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net unrealized gain loss investment directly own determined end report period gain loss ownership interest investment fund account equity method investment report quarter lag investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical table content similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allow company recognize revenue sale vaccine government stockpile sale meet criterion revenue recognition accounting guidance customer billand hold arrangement company revenue billandhold arrangement recognize control transfer customer customer physical possession good control transfer billandhold arrangement request customer product identify belong customer ready physical transfer product direct use customer certain circumstance customer inspect accepted product company facility certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate billion billion billion chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue accrue balance relative provision chargeback rebate include account receivable accrue current liability table content million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside payment term typically day day certain market long payment term note disaggregate revenue disclosure depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development cost include property plant equipment addition company capitalize certain cost incur implement cloud computing arrangement consider service agreement include asset capitalize software cost amortize period range year long live generally associate enterprisewide project implement multiple year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible acquire intangible include product product right trade name patent license initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounte table content future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result contingent consideration certain company acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale transaction account business combination fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning significant event increase decrease probability achieve development regulatory milestone increase decrease project cash flow result correspond increase decrease fair value relate contingent consideration obligation transaction account acquisition asset business contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve research development research development expense incur nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration associate iprd asset research development expense include upfront milestone payment relate asset acquisition licensing transaction involve clinical development program receive regulatory approval collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner merck principal sale transaction party company recognize sale cost sale sell general administrative expense gross basis profit sharing amount pay collaborative partner record cost sale collaborative partner principal sale transaction party company record profit sharing amount receive collaborative partner alliance revenue sale alliance revenue record net cost sale include adjustment share commercialization cost partner accordance collaboration agreement adjustment determine compare commercialization cost merck incur directly report sell general administrative expense cost collaborative partner incur research development cost merck incur relate collaboration record research development expense cost reimbursement collaborative partner payment receive collaborative partner share cost pursuant term collaboration agreement record increase decrease research development expense table content addition term collaboration agreement require company payment base achievement certain developmental regulatory approval commercial milestone upfront milestone payment payable merck collaborative partner prior regulatory approval expense incur include research development expense payment collaborative partner subsequent regulatory approval capitalize amortize estimate useful life correspond intangible asset cost sale provide future cash flow support amount capitalize salesbased milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup probable achieve amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize cost sale remain useful life subject impairment testing sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income continue operation company account tax effect tax global intangible lowtaxed income gilti certain foreign subsidiary income tax provision period tax arise use estimate consolidated financial statement prepare conformity accounting principle generally accept gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation table content recently adopt accounting standard december financial accounting standard board fasb issue amend guidance accounting reporting income taxis guidance intend simplify accounting income taxis remove exception relate certain intraperiod tax allocation defer tax liability clarify guidance primarily related evaluate stepup tax basis goodwill business combination reflect enact change tax law rate annual effective tax rate company adopt new guidance effective january impact company consolidate financial statement adoption january fasb issue new guidance intend clarify certain interaction accounting standard relate equity security equity method investment certain derivative guidance address accounting transition equity method accounting measure certain purchase option forward contract acquire investment company adopt new guidance effective january impact company consolidate financial statement adoption august fasb issue amend guidance accounting convertible instrument contract entity equity guidance remove separation model convertible debt instrument prefer stock amend requirement conversion option classify equity amend diluted earning share eps calculation certain convertible debt instrument amend guidance effective interim annual period application amendment new guidance apply modify retrospective retrospective basis impact company consolidate financial statement adoption january recently issue accounting standard adopt march fasb issue optional guidance ease potential burden account recognize effect reference rate reform financial reporting subsequently issue clarify amendment guidance provide optional expedient exception accounting contract hedge relationship transaction reference london interbank offer rate libor reference rate expect discontinue reference rate reform optional guidance effective issuance apply prospective basis time january december company currently evaluate impact adoption consolidate financial statement company progress evaluation libor cessation exposure include review debtrelate contract lease business development licensing arrangement royalty agreement company amend certain agreement continue review agreement potential impact regard debtrelate exposure particular exist interest rate swap link libor mature company evaluate impact liborbase debt base evaluation far company anticipate material impact consolidate financial statement result reference rate reform october fasb issue amend guidance require acquire entity recognize measure contract asset liabilitie business combination accordance exist revenue recognition guidance amend guidance effective interim annual period apply prospectively early adoption permit retrospective basis begin fiscal year adoption adoption guidance material impact company consolidate financial statement prior acquisition impact future period dependent contract asset contract liability acquire future business combination november fasb issue new guidance increase transparency transaction government account apply grant contribution accounting model analogy guidance require annual disclosure transaction include nature transaction significant term condition account treatment impact company financial statement guidance effective annual period beginning apply prospective retrospective basis company currently evaluate impact adoption consolidate financial statement spinoff organon june merck complete spinoff organon distribution organon publicly trade stock company shareholder connection spinoff merck shareholder receive onetenth share organon common stock share merck common stock hold shareholder table content distribution expect qualify treat tax free merck shareholder federal income tax purpose indebtedness billion principal consist term loan senior note issue connection spinoff assume organon merck long obligor organon debt financing arrangement cash proceed billion distribute organon merck connection spinoff connection spinoff merck organon enter separation distribution agreement enter agreement effect spinoff provide framework relationship merck organon spinoff include transition service agreement tsa manufacturing supply agreement msa trademark license agreement intellectual property license agreement employee matter agreement tax matter agreement certain commercial agreement tsa merck provide organon service similarly organon provide merck service provision service tsa generally terminate month follow spinoff merck organon enter series interim operating agreement pursuant jurisdiction merck hold license permit right connection marketing import andor distribution organon product prior separation merck continue market import distribute product time relevant license permit transfer organon interim operating agreement accordance separation distribution agreement merck continue operation affect market behalf organon organon receive economic benefit burden activity additionally merck organon enter number msas pursuant merck manufacture supply certain active pharmaceutical ingredient organon toll manufacture supply certain formulate pharmaceutical product organon package label certain finished pharmaceutical product organon similarly organon merck enter number msas pursuant organon manufacture supply certain formulate pharmaceutical product merck package label certain finished pharmaceutical product merck term msa range initial duration year year amount include consolidated statement income msa include sale million relate cost sale million amount include consolidated statement income tsas immaterial organon agreement million december reflect current asset organon agreement million december include accrued current liability result women health biosimilar establish brand business previously include pharmaceutical segment contribute organon spinoff interest expense relate debt issuance reflect discontinued operation company consolidated statement income income discontinue operation net taxis amount attributable noncontrolle interest june date spinoff prior period recast reflect presentation result spinoff organon merck incur separation cost million million include income discontinue operation net taxis amount attributable noncontrolle interest cost primarily relate professional fee separation activity finance tax legal information technology function investment banking fee december asset liabilities associate business classify asset liability discontinue operation consolidated balance sheet table content detail income discontinue operation net taxis amount attributable noncontrolle interest follow year end december sale cost expense cost sale sell general administrative research development restructuring cost income expense net income discontinue operation tax tax provision income discontinue operation net taxis income discontinue operation attributable noncontrolle interest income discontinue operation net taxis amount attributable noncontrolle interest reflect amount june spinoff date detail asset liability discontinue operation follow december cash cash equivalent account receivable allowance doubtful account inventory current asset current asset discontinue operation property plant equipment net goodwill intangible net asset noncurrent asset discontinue operation trade account payable accrue current liability income taxis payable total current liability discontinue operation defer income taxis noncurrent liability noncurrent liability discontinue operation result spinoff organon merck distribute net liability billion june consist debt billion describe goodwill billion property plant equipment million cash million inventory million intangible net million net liability million spinoff result net decrease aocl million consist million derecognition net loss foreign currency translation adjustment million associate employee benefit plan distribution net liability reduction aocl result net billion increase paidin capital table content expense curtailment settlement termination benefit provide certain employee incur connection spinoff note additionally outstanding merck stock option restrict stock unit rsus performance share unit psus vest unvested convert adjust merck award current merck employee organon awards organon employee note acquisition research collaboration license agreement company continue pursue acquisition establishment external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share arrangement contingent occurrence certain future event link success asset development company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result transaction november merck acquire acceleron pharma inc acceleron publicly trade biopharmaceutical company total consideration billion acceleron evaluating transform growth factor tgfbeta superfamily protein know play central role regulation cell growth differentiation repair acceleron lead therapeutic candidate sotatercept novel mechanism action potential improve shortterm andor longterm clinical outcome patient pulmonary arterial hypertension pah sotatercept phase trial addon current standard care treatment pah previous agreement assume merck bristol myers squibb bms grant exclusive license develop commercialize sotatercept outside pulmonary hypertension field merck eligible receive contingent milestone royalty payment merck retain worldwide exclusive right develop commercialize sotatercept field agreement provide merck pay royalty future sale sotatercept field bms addition sotatercept acceleron portfolio include reblozyl luspatercept firstinclass erythroid maturation recombinant fusion protein approve europe canada australia treatment anemia certain rare blood disorder evaluate phase phase trial additional indication hematology therapy reblozyl develop commercialize global collaboration bms connection ongoing collaboration merck receive sale royalty bms increase maximum base sale level royalty reduce early patent expiry generic entry indicationbyindication basis market merck eligible receive future contingent milestone payment include million regulatory milestone million salesbased milestone transaction account business combination company incur million cost directly relate acquisition acceleron consist primarily sharebase compensation payment settle nonveste equity award attributable postcombination service severance investment bank legal fee cost include sell general administrative expense research development cost table content estimate fair value asset acquire liability assume acceleron follow november cash cash equivalent investment identifiable intangible asset iprd sotatercept product product right reblozyl year useful life defer income tax liability net asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate sotatercept reblozyl determine income approach specifically multiperiod excess earning method future probabilityweighte net cash flow discount present value utilize discount rate sotatercept reblozyl actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate pharmaceutical segment goodwill deductible tax purpose april merck acquire pandion therapeutics inc pandion clinicalstage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease pandion advance pipeline precision immune modulator target critical immune control node total consideration pay billion include million cost primarily comprise sharebased compensation payment settle equity award transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction future contingent payment associate acquisition march merck gilead sciences inc gilead enter agreement jointly develop commercialize longacting treatment hiv combine merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir gilead investigational capsid inhibitor lenacapavir collaboration initially focus longacte oral formulation longacte injectable formulation combination product formulation potentially add collaboration mutually agree upfront payment party enter agreement term agreement merck gilead share operational responsibility development commercialization marketing cost future revenue global development commercialization cost share gilead merck oral injectable formulation program longacte oral product gilead lead commercialization merck lead commercialization rest world longacte injectable product merck lead commercialization gilead lead commercialization rest world gilead merck copromote certain major market merck gilead share global product revenue equally product revenue surpass certain preagreed formulation revenue tier pass billion year net product sale oral combination revenue split adjust gilead merck revenue threshold pass billion year net product sale injectable combination revenue split adjust gilead merck revenue threshold potential combination investigational lenacapavir investigational islatravir gilead option license certain merck investigational oral integrase inhibitor develop combination lenacapavir reciprocally merck option license certain gilead investigational oral integrase inhibitor develop combination islatravir company exercise option investigational oral integrase inhibitor company follow completion phase clinical trial integrase inhibitor exercise option company split development cost revenue nonexercise company decide optout december food drug administration fda place partial clinical hold investigational new drug application certain oral implant injectable formulation islatravir base table content observation decrease total lymphocyte tcell count participant receive islatravir clinical study result hold merck gilead decision stop dose participant phase clinical study evaluate islatravir lenacapavir people live hiv virologically suppress antiretroviral therapy company assess different dosing islatravir combination lenacapavir provide onceweekly oral therapy option people live hiv merck gilead remain committed collaboration january merck enter exclusive license research collaboration agreement artiva biotherapeutics inc artiva discover develop manufacture carnk cell target certain solid tumor artivas proprietary platform merck artiva agree engage different research program cover collaboration target merck sole responsibility development commercialization activity include regulatory filing approval term agreement merck upfront payment million include research development expense license right collaboration target agree upfront payment million license right collaboration target select merck accept artiva addition artiva eligible receive future contingent milestone payment span collaboration target aggregate million developmental milestone million regulatory milestone billion salesbase milestone agreement provide merck pay tiere royalty range future sale transaction december merck acquire oncoimmune privately hold clinicalstage biopharmaceutical company upfront payment million oncoimmune lead therapeutic candidate evaluate treatment patient hospitalize covid transaction account acquisition asset agreement prior completion acquisition oncoimmune spunout certain right asset unrelated program new entity own exist shareholder oncoimmune connection closing acquisition merck invest million ownership interest new entity value million result million premium merck recognize net liability million company record research development expense million relate transaction merck receive feedback fda additional datum need support potential emergency use authorization eua application company expect available half give timeline technical clinical regulatory uncertainty availability number medicine patient hospitalize covid need concentrate merck resource accelerate development manufacture viable therapeutic vaccine merck decide discontinue development treatment covid discontinuation company record charge million reflect cost sale relate fix asset material write recognition liability purchase commitment december merck acquire velosbio inc velosbio privately hold clinicalstage biopharmaceutical company billion velosbio lead investigational candidate zilovertamab vedotin antibodydrug conjugate target receptor tyrosine kinaselike orphan receptor ror currently evaluate treatment patient hematologic malignancy solid tumor transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction company record adjustment amount result reduction research development expense million increase total consideration pay million increase net asset record million september merck seagen inc seagen announce oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin investigational antibodydrug conjugate target liv currently phase clinical trial collaboration pursue broad joint development program evaluate ladiratuzumab vedotin monotherapy combination keytruda pembrolizumab triplenegative breast cancer hormone receptorpositive breast cancer livexpresse solid tumor company equally share profit worldwide term agreement table content merck upfront payment million billion equity investment million share seagen common stock price share merck record million research development expense relate transaction reflect upfront payment million premium relate equity share base price seagen common stock closing date seagen eligible receive future contingent milestone payment billion include million development milestone billion salesbase milestone concurrent transaction seagen grant merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment human epidermal growth factor receptor herpositive cancer asia middle east latin america region outside canada europe merck responsible marketing application seek approval territory support positive result herclimb clinical trial merck cofund portion tukysa global development plan encompass ongoing plan trial herpositive cancer include breast colorectal gastric cancer set forth global product development plan merck solely fund conduct countryspecific clinical trial necessary support anticipate regulatory application territory term agreement merck upfront payment aggregate million record research development expense seagen eligible receive future contingent regulatory approval milestone million receive tiere royalty range base annual sale level tukysa merck territory additionally september merck acquire biologic manufacturing facility locate dunboyne ireland takeda pharmaceutical company limit million million transaction account acquisition asset merck record property plant equipment million net asset million future contingent payment associate acquisition july merck acquire right sentinel flavor tabs sentinel spectrum chew virbac corporation million sentinel product provide protection common parasite dog transaction account acquisition asset merck recognize intangible asset million relate currently market product inventory million acquisition date estimate fair value identifiable intangible asset relate currently market product determine income approach actual cash flow likely different assumed intangible asset relate currently market product amortize estimate useful life year future contingent payment associate acquisition july merck ridgeback biotherapeutic ridgeback closely hold biotechnology company close collaboration agreement develop molnupiravir orally available antiviral candidate clinical development treatment patient covid note additional information relate collaboration june merck acquire privately hold themis bioscience gmbh themis company focus vaccine include covid vaccine candidate immunemodulation therapie infectious disease cancer million acquisition originally provide merck additional contingent payment million transaction account business combination company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream appropriate discount rate dependent nature time milestone payment merck recognize intangible asset iprd million cash million defer tax asset million net liability million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assume january company announce discontinue development discuss result company record iprd impairment charge million research development expense company record reduction research development expense result decrease relate liability contingent consideration million future contingent milestone payment reduce million aggregate include million development milestone million regulatory approval milestone million commercial milestone table content merck international aids vaccine initiative inc iavi nonprofit scientific research organization dedicate address urgent unmet global health challenge announce collaboration develop investigational vaccine sarscov study prevention covid agreement provide upfront payment merck million provide future contingent payment base sale merck sign agreement biomedical advanced research development authority barda office assistant secretary preparedness response agency department health human service provide initial funding support merck effort january company announce discontinue development discuss january company announce discontinuation development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccine discontinuation company record charge million million reflect cost sale relate fix asset material write recognition liability purchase commitment remain million cost reflect research development expense represent amount relate themis acquisition note iprd impairment charge partially offset reduction relate liability contingent consideration january merck acquire arqule inc arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease total consideration pay billion include million sharebased compensation payment settle equity award attributable precombination service cash pay transaction cost behalf arqule company incur million cost directly relate acquisition arqule consist entirely sharebased compensation payment settle nonveste equity award attributable postcombination service cost include sell general administrative expense arqule lead investigational candidate nemtabrutinib novel oral bruton tyrosine kinase btk inhibitor currently evaluate treatment bcell malignancy transaction account business combination estimate fair value asset acquire liability assume arqule follow january cash cash equivalent iprd nemtabrutinib licensing arrangement arq defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value nemtabrutinib determine income approach future probabilityweighte net cash flow discount present value utilize discount rate actual cash flow likely different assumed goodwill allocate pharmaceutical segment deductible tax purpose merck record million intangible asset impairment charge related nemtabrutinib note transaction july merck acquire peloton therapeutics inc peloton clinicalstage biopharmaceutical company focus development novel small molecule therapeutic candidate target hypoxiainducible factor hif treatment patient cancer nononcology disease merck upfront payment billion transaction account acquisition asset merck record cash million defer tax liability million net liability million acquisition table content date research development expense million relate transaction peloton shareholder receive million milestone payment merck commercial sale peloton lead candidate welireg belzutifan approve monotherapy august peloton shareholder eligible receive million regulatory approval combination therapy billion salesbased milestone april merck acquire antelliq corporation antelliq leader digital animal identification traceability monitoring solution solution help veterinarian farmer pet owner gather critical datum improve management health wellbee livestock pet merck pay billion acquire outstanding share antelliq spend billion repay antelliqs debt transaction account business combination estimate fair value asset acquire liability assume antelliq follow april cash cash equivalent account receivable inventory property plant equipment identifiable intangible asset useful life range year defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate primarily trade name determine income approach future probabilityweighte net cash flow discount present value utilize discount rate actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate animal health segment goodwill deductible tax purpose company incur million transaction cost directly relate acquisition antelliq consist largely advisory fee reflect sell general administrative expense april merck acquire immune design latestage immunotherapy company employ nextgeneration vivo approach enable bodys immune system fight disease million cash transaction account business combination merck recognize intangible asset million cash million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assumed collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner party arrangement active participant expose significant risk reward dependent commercial success activity collaboration merck significant collaborative arrangement discuss astrazeneca merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer type independently merck astrazeneca develop commercialize lynparza combinations respective pdl medicine keytruda imfinzi company jointly develop table content commercialize astrazenecas koselugo selumetinib multiple indication term agreement astrazeneca merck share development commercialization cost lynparza koselugo monotherapy nonpdlpd combination therapy opportunitie profit lynparza koselugo product sale generate monotherapie combination therapy share equally astrazeneca principal lynparza koselugo sales transaction merck records share lynparza koselugo product sale net cost sale commercialization cost alliance revenue share development cost associate collaboration research development expense reimbursement receive astrazeneca research development expense recognize reduction research development cost agreement merck upfront payment astrazeneca payment multiyear period certain license option addition agreement provide contingent payment merck astrazeneca relate successful achievement salesbase regulatory milestone merck salesbased milestone payment astrazeneca aggregate million million respectively december salesbase milestone payment accrue pay total million potential future salesbase milestone payment billion accrue deem company probable time lynparza receive regulatory approval trigger capitalize milestone payment million million respectively aggregate merck astrazeneca potential future regulatory milestone payment billion remain agreement intangible asset balance relate lynparza includes capitalize salesbased regulatory milestone payment billion december include intangible net amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sale sell general administrative research development december receivables astrazeneca include current asset payable astrazeneca include trade account payable accrue current liability represent amortization capitalize milestone payment include accrue milestone payment eisai merck eisai ltd eisai announce strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor discover eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai record lenvima product sale globally eisai principal lenvima sale transaction merck eisai share applicable profit equally merck record share lenvima product sale net cost sale commercialization cost alliance revenue expense incur codevelopment share company accordance collaboration agreement reflect research development expense certain expense incur solely merck eisai table content shareable collaboration agreement include cost incur excess agree cap cost relate certain combination study keytruda lenvima agreement merck upfront payment eisai payment multiyear period certain option right final million option payment march addition agreement provide contingent payment merck eisai relate successful achievement salesbase regulatory milestone merck salesbased milestone payment eisai aggregate million million million respectively december salesbase milestone payment accrue pay total million potential future sale base milestone payment billion accrue deem company probable time lenvima receive regulatory approval trigger capitalize milestone payment million million respectively merck eisai december regulatory approval milestone payment million accrue pay potential future regulatory milestone payment million remain agreement intangible asset balance relate lenvima includes capitalize salesbased regulatory milestone payment billion december include intangible net amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue lenvima cost sale sell general administrative research development december receivables eisai include current asset payable eisai include accrue current liability payable eisai include noncurrent liability represent amortization capitalize milestone payment include accrue milestone future option payment include accrue milestone payment bayer company enter worldwide clinical development collaboration bayer bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas riociguat company implement joint development commercialization strategy collaboration include development bayer verquvo vericiguat approve january japan june july agreement bayer commercialize adempas americas merck commercialize rest world verquvo merck commercialize bayer commercialize rest world company share development cost profit sale merck record sale adempas verquvo marketing territory alliance revenue alliance revenue represent merck share profit sale adempas verquvo bayer marketing territory product sale net cost sale commercialization cost cost sale include bayer share profit sale merck marketing territory addition agreement provide contingent payment merck bayer relate successful achievement salesbase milestone merck salesbased milestone payment bayer million follow approval verquvo note merck determine probable sale adempas verquvo future trigger remain million salesbase milestone table content payment outstanding agreement accordingly merck record liability million corresponding increase intangible asset relate collaboration merck recognize million cumulative amortization catchup expense relate recognition milestone january merck final milestone payment bayer intangible asset balance relate adempas includes acquire intangible asset balance capitalize salesbased milestone payment attribute adempas verquvo reflect portion final salesbase milestone payment attribute verquvo million million respectively december include intangible net asset amortize estimate useful life adempas verquvo support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue adempasverquvo net sale adempas record merck net sale verquvo record merck total sale cost sale sell general administrative research development december receivables bayer include current asset payable bayer include accrued current liability include amortization intangible asset include million cumulative amortization catchup expense note addition cost sale period include bayer share profit sale merck marketing territory include accrue milestone payment ridgeback biotherapeutic july merck ridgeback closely hold biotechnology company enter collaboration agreement develop molnupiravir orally available antiviral candidate clinical development treatment patient covid merck gain exclusive worldwide right develop commercialize molnupiravir relate molecule term agreement ridgeback receive upfront payment eligible receive future contingent payment dependent achievement certain developmental regulatory approval milestone agreement provide merck reimburse ridgeback portion certain thirdparty contingent milestone payment royaltie net sale profit share calculation merck principal sale transaction recognize sale relate cost profit sharing amount record cost sale profit collaboration split equally partner reimbursement ridgeback share research development cost deduct ridgeback share profit reflect decrease research development expense december fda grant eua molnupiravir previously announce procurement agreement government merck agree supply million course molnupiravir government eua approval fda approximately course deliver procurement molnupiravir support federal fund additionally december japans ministry health labor welfare grant special approval emergency japan molnupiravir supply agreement japanese government purchase million course molnupiravir approximately course deliver november medicine healthcare product regulatory agency united kingdom grant conditional marketing authorization molnupiravir government commit purchase total million course molnupiravir approximately course deliver merck enter advance purchase supply agreement molnupiravir market table content merck ridgeback commit provide timely access molnupiravir globally comprehensive supply access approach include invest risk produce millions course therapy tiere pricing base ability government finance health care enter supply agreement government note allocate million course therapy united nations childrens fund unicef use adult grant voluntary license generic manufacturers medicine patent pool mpp generic molnupiravir available low middleincome country follow local regulatory authorization approval merck ridgeback emory university receive royalty sale molnupiravir mpp agreement molnupiravir invent emory university license ridgeback long covid remain classified public health emergency international concern world health organization summarize financial information relate collaboration follow year end december molnupiravir sale cost sale sell general administrative research development december payable ridgeback include accrued current liability include royalty expense amortization capitalize milestone payment include upfront payment include accrue royalty milestone payment restructuring merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructuring program action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company estimate approximately cumulative pretax cost result cash outlay primarily relate employee separation expense facility shutdown cost approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company record total pretax cost million million million related restructuring program activity inception restructuring program december merck record total pretax accumulate cost approximately billion company expect record charge approximately million related restructuring program segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate cost depreciation total year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate accelerated depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck recording accelerate depreciation revise useful life site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include asset abandonment facility shutdown relate cost pretax gain loss result sale facility relate asset additionally activity include certain employeerelate cost associate pension postretirement benefit plan note sharebased compensation follow table summarize charge spend relate restructure program activity separation accelerate cost depreciation total restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december remain cash outlay expect substantially complete end table content financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen british pound canadian dollar swiss franc exposure develop country currency include chinese renminbi company enter forward contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year table content company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci effect company net investment hedge oci consolidated statement income show pretax gain loss recognize pretax gain loss recognize income expense net amount exclude comprehensive income effectiveness testing year end december net investment hedging relationship foreign exchange contract eurodenominate note amount reclassify aocl income relate sale subsidiary interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk january interest rate swap total notional billion mature swap effectively convert company billion fixedrate note variable rate debt december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note interest rate swap mature february interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract note discussion pende discontinuation libor reference rate reform cash flow contract report operating activity consolidate statement cash flow table content table present location amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge december cumulative fair value hedge adjustment increase decrease include carrying hedge liability carry balance sheet line item hedge item include loan payable current portion longterm debt longterm debt present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative dollar derivative dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract current asset interest rate swap contract asset foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument foreign exchange contract current asset foreign exchange contract accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross amount subject offset master netting arrangement offset consolidated balance sheet cash collateral postedreceive net amount table content table provide information location pretax gain loss derivative designate fair value cash flow hedge relationship sale income expense net comprehensive income loss year end december financial statement line item effect fair value cash flow hedge record gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument impact cash flow hedging relationship foreign exchange contract gain loss recognize oci derivative decrease increase sale result aocl reclassification interest rate contract gain recognize income expense net derivative loss recognize oci derivative interest expense component income expense net table provide information income statement effect derivative designate hedge instrument derivative pretax gain loss recognize income year end december derivative designate hedge instrument income statement caption foreign exchange contract income expense net foreign exchange contract sale interest rate contract income expense net forward contract relate seagen common stock research development expense derivative contract primarily mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate include loss forward exchange contract enter conjunction spinoff organon derivative serve economic hedge forecast transaction derivative serve economic hedge rise treasury rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aocl sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealized amortize fair amortize fair cost gain loss value cost gain loss value government agency security foreign government bond corporate note bond total debt security publicly trade equity security total debt publicly trade equity security unrealize net loss record income expense net equity security hold december million unrealize net gain record income expense net equity security hold december million december company million million respectively equity investment readily determinable fair value include asset company record unrealize gain equity investment base favorable observable price change transaction involve similar investment investee record unrealize loss base unfavorable observable price change include income expense net company record unrealized gain million unrealize loss million relate certain equity investment hold december company record unrealized gain million unrealize loss million relate certain investment hold december cumulative unrealized gain cumulative unrealized loss base observable price change investment equity investment readily determinable fair value hold december million million respectively december company billion million respectively record asset equity security hold ownership interest investment fund gain loss record income expense net relate investment fund billion million million year end december respectively fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement level level level total level level level total asset investment foreign government bond publicly trade equity security asset government agency security corporate note bond publicly trade equity security derivative asset forward exchange contract purchase currency option interest rate swap total asset liability liabilities contingent consideration derivative liability forward exchange contract write currency option total liability investment include asset restrict use include payment benefit employee benefit plan fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant december cash cash equivalent include cash equivalent billion consider level fair value hierarchy table content contingent consideration summarize information change fair value liability contingent consideration associate business combination follow fair value january addition change estimate fair value payment fair value december record cost sale research development expense income expense net include cumulative translation adjustment balance december include million record current liability amount expect pay month december million million respectively liability relate termination sanofi pasteur msd joint venture termination merck record liability contingent future royalty payment net sale merck product previously sell joint venture december fair value liability determine utilize estimate time project cash flow riskadjusted discount rate present value cash flow addition contingent consideration relate acquisition themis note payment contingent consideration year relate sanofi pasteur msd liability describe fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale europe china primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor global economic condition include volatility associate international sovereign economy associate impact financial market business company customer large account receivable balance mckesson corporation amerisourcebergen corporation cardinal health inc represent approximately respectively total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale company account receivable factoring agreement financial institution certain country sell account receivable company factor billion billion account receivable december respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million million table content respectively behalf financial institution reflect restrict cash current asset relate obligation remit cash accrue current liability company remit cash financial institution january respectively net cash flow relate collection report financing activity consolidate statement cash flow cost factoring account receivable minimis derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty cash collateral receive company counterpartie million december obligation return collateral record accrue current liability cash collateral advanced company counterpartie million december inventory inventory december consist finished good raw material work process supply total approximate current cost decrease lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical animal health total balance january acquisition divestiture balance december acquisition balance december include cumulative translation adjustment goodwill balance accumulate goodwill impairment loss million december addition goodwill pharmaceutical segment primarily relate acquisition acceleron addition goodwill pharmaceutical segment primarily relate acquisition arqule themis note information acquisition table content acquire intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right iprd trade name license acquire intangible include product product right iprd trade name patent license initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life significant acquire intangible net basis relate human health market product include product product right december include reblozyl billion zerbaxa million gardasilgardasil million bridion million dificid million sivextro million simponi million additionally company billion net acquire intangible related animal health market product december billion relate primarily trade name obtain acquisition antelliq note december iprd primarily relate sotatercept billion obtain acquisition acceleron note nemtabrutinib billion obtain acquisition arqule note gefapixant million obtain acquisition afferent pharmaceutical significant net intangible asset include license december include lynparza billion relate collaboration astrazeneca lenvima billion relate collaboration eisai adempas million relate collaboration bayer verquvo million relate collaboration bayer note additional information relate intangible asset associate collaborations company record impairment charge billion cost sale relate zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection december company temporarily suspend sale zerbaxa subsequently issue product recall follow identification product sterility issue recall constitute trigger event require evaluation zerbaxa intangible asset impairment company revise cash flow forecast zerbaxa utilize certain assumption return market timeline anticipate uptake sale revise cash flow forecast indicate zerbaxa intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate zerbaxa compare related carrying value result impairment charge note company wroteoff inventory million cost sale relate zerbaxa recall phase resupply zerbaxa initiate fourth quarter company record impairment charge relate market product intangible million million relate sivextro tedizolid phosphate product treatment acute bacterial skin skin structure infection cause designate susceptible grampositive organism reorganization reprioritization internal sale force company decision cease promotion sivextro market end decision result reduce cash flow projection sivextro indicate sivextro intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate sivextro compare related carrying value result impairment charge note iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing table content completion abandonment project successful completion iprd project company separate determination useful life asset begin amortization company record million iprd impairment charge research development expense relate nemtabrutinib novel oral btk inhibitor currently evaluate treatment bcell malignancy obtain connection acquisition arqule note merck annual impairment assessment iprd intangible asset company estimate current fair value nemtabrutinib utilize project future cash flow market participant assumption derive forecast cash flow update reflect current competitive landscape nemtabrutinib include increase expect development cost additional clinical trial datum need develop nemtabrutinib delay anticipate launch date nemtabrutinib collectively reduce project future cash flow estimate fair value additionally discount rate utilize determine current fair value asset reduce reflect current risk profile asset revise estimate fair value nemtabrutinib compare related carrying value result iprd impairment charge note remain iprd intangible asset relate nemtabrutinib billion assumption estimate fair value nemtabrutinib prove incorrect development nemtabrutinib progress anticipate adversely affect project future cash flow company record additional impairment charge future charge material company record million iprd impairment charge relate decision discontinue development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccines discontinuation development program result reversal relate liability contingent consideration million company record million iprd impairment charge million relate writeoff intangible asset balance program obtain connection acquisition iomet pharma ltd follow review clinical trial result conduct merck external clinical trial result similar compound discontinuation clinical development program result reversal relate liability contingent consideration million iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record cost sale billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion loan payable longterm debt lease loan payable loan payable december include billion note million longdate note subject repayment option holder loan payable december include billion note billion commercial paper borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively table content longterm debt longterm debt december consist note note note note note note note note note note note note eurodenominate note note note note note note note eurodenominate note eurodenominate note eurodenominate note note note note debenture note debenture debenture note note present table include borrowing variable rate result effective interest rate zero respectively exception debenture note list table redeemable merck option time vary redemption price december company issue billion principal senior unsecured note consist billion note billion note billion note billion note billion note merck net proceed offer note note note note general corporate purpose include repayment outstanding commercial paper borrowing include commercial paper borrowing connection mercks acquisition acceleron indebtedness merck allocate equal net proceed offer note finance refinance project partnership company priority environmental social governance esg area table content effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply covenant december company compliance covenant aggregate maturity longterm debt year follow billion billion billion billion billion interest payment relate debt obligation follow million million million million million company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility lease company operating lease primarily manufacture facility research development facility corporate office employee housing vehicle certain equipment company determine arrangement lease inception evaluate contract embed lease company exercise judgment determine explicit implicit identify asset contract merck control use asset embed lease primarily associate contract manufacturing organization immaterial lease term include option extend terminate lease reasonably certain merck exercise option real estate lease facility average remain lease term seven year include option extend lease year applicable vehicle lease generally effect year company record shortterm lease lease initial term month balance sheet merck currently shortterm lease lease expense operating lease payment recognize straightline basis term lease operating lease asset liability recognize base present value lease payment lease term company lease readily determinable implicit discount rate company use incremental borrowing rate calculate present value lease payment asset class quarterly basis update incremental borrowing rate determine base average remain lease term asset class company pretax cost debt term update rate asset class apply prospectively new lease company separate lease component payment rent real estate taxis insurance cost nonlease component commonarea maintenance cost event agreement contain merck include lease nonlease component purpose calculate rightofuse asset relate lease liability nonlease component fix vehicle lease employee housing company apply portfolio approach account operating lease asset liability certain company lease agreement contain variable lease payment adjust periodically inflation actual operating expense true up compare estimate amount amount immaterial sublease income activity relate sale leaseback transaction immaterial merck lease agreement contain material residual value guarantee material restrictive covenant operate lease cost million million million cash pay amount include measurement operating lease liability million million million operating lease asset obtain exchange lease obligation million million million table content supplemental balance sheet information relate operating lease follow december asset asset liability accrue current liability noncurrent liability weightedaverage remain lease term year weightedaverage discount rate include prepaid lease relate lease liability maturity operating lease liability follow total lease payment imputed interest december company enter additional real estate operating lease commence obligation associate lease total million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter opinion company unlikely resolution matter material company financial condition result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability table content product liability litigation fosamax previously disclose merck defendant product liability lawsuit involve fosamax fosamax litigation december approximately case pende merck federal multidistrict litigation femur fracture mdl state court plaintiff vast majority case generally allege sustained femur fracture andor bone injury femur fracture association use fosamax march femur fracture mdl court dismiss prejudice approximately case preemption ground plaintiff approximately case appeal decision court appeal circuit circuit march circuit issue decision reverse femur fracture mdl court preemption ruling remand appeal case femur fracture mdl court supreme court decide circuit incorrectly conclude issue preemption resolve jury accordingly vacate judgment circuit remand proceeding circuit address issue manner consistent supreme courts opinion november circuit remand case district court order allow court determine instance plaintiff state law claim preempt federal law standard describe supreme court opinion briefing issue close party await decision district court discovery presently stay femur fracture mdl spinoff organon organon require indemnify merck liability relate arise result fosamax litigation januviajanumet previously disclose merck defendant product liability lawsuit involve januvia andor janumet december merck aware approximately product user allege januvia andor janumet cause development pancreatic cancer injury claim file multidistrict litigation district court southern district california mdl march mdl court issue omnibus order grant defendant summary judgment motion base preemption failure establish general causation grant defendant motion exclude plaintiff expert witness plaintiff appeal order time half claim dismiss prejudice merck october court appeal ninth circuit dismiss appeal merck codefendant outside mdl majority claim file coordinated proceeding superior court california county los angeles california state court april court california issue omnibus order grant defendant summary judgment motion grant defendant motion exclude plaintiff expert witness december product user claim pende merck state court california include illinois june illinois trial court deny merck motion summary judgment base federal preemption merck appeal illinois appellate court affirm december merck file petition leave appeal illinois supreme court february april illinois supreme court stay consideration pende petition appeal supreme court issue opinion merck sharp dohme corp albrecht relate fosamax matter discuss merck file opinion albrecht illinois supreme court june petition leave appeal decide september illinois supreme court direct intermediate appellate court reconsider early rule illinois appellate court issue favorable decision conclude consistent albrecht preemption present legal question resolve court illinois appellate court issue mandate state trial court december schedule case management conference take action addition claim note company agree toll statute limitation approximately additional claim company intend continue defend remain lawsuit table content governmental proceeding previously disclose fall company receive record subpoena attorney office district vermont usao pursuant section health insurance portability accountability act hipaa relate investigation potential health care offense subpoena seek information relate actual potential business relationship arrangement merck practice fusion inc pfi cloudbase electronic health record ehr company acquire allscripts january company cooperate government respond subpoena subsequently merck receive second record subpoena usao broaden government information request seek information relate merck relationship ehr company shortly usao serve civil investigation demand cid merck similarly seek information company relationship ehr vendor cid explain government conduct false claim act investigation concern merck andor pfi submit claim federal health care program violate federal antikickback statute merck cooperate government investigation previously disclose april merck receive set investigative interrogatory california attorney general office pursuant investigation conduct agreement allegedly affect delay competition lantus insulin market interrogatory seek information concern merck development insulin glargine product subsequent termination merck patent litigation sanofi concern lantus resolution litigation merck cooperate california attorney general investigation previously disclose june merck receive cid department justice cid request answer interrogatory document temperature excursion thirdparty storage facility contain certain merck product merck cooperate government investigation intend produce information andor document necessary response cid previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate previously disclose time time company receive inquiry subject preliminary investigation activity competition governmental authority market outside authority include regulator administrative authority law enforcement similar official preliminary investigation activity include site visit formal informal request demand document material inquiry interview similar matter certain preliminary inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require commercial litigation zetia antitrust litigation previously disclose merck msd schering corporation scheringplough corporation msp singapore company llc collectively merck defendant defendant putative class action optout lawsuit file behalf direct indirect purchaser zetia allege violation federal state antitrust law state statutory common law cause action case consolidated pretrial purpose federal multidistrict litigation judge rebecca beach smith eastern district virginia december court deny merck defendant motion dismiss stay direct purchaser putative class action pende bilateral arbitration august district court adopt report recommendation magistrate judge respect merck defendant motion dismiss nonarbitration issue grant deny merck defendant motion dismiss addition june representative putative direct purchaser class file amend complaint august retailer optout plaintiff file amend complaint december district court grant merck defendant motion dismiss extent motion seek dismissal claim overcharge pay entity table content purchase generic ezetimibe par pharmaceutical inc par pharmaceutical dismiss claim overcharge november direct purchaser plaintiff indirect purchaser plaintiff file motion class certification august district court grant direct purchaser motion class certification certify class direct purchaser august fourth circuit vacate district court class certification order remand proceeding consistent court rule september direct purchaser plaintiff file renew motion class certification january magistrate judge recommend district court deny motion class certification february direct purchaser plaintiff file objection recommendation briefing objection ongoing august merck defendant file motion summary judgment motion plaintiff file motion partial summary judgment motion motion fully brief court hear argument certain motion court hold additional hearing motion trial matter adjourn august magistrate judge recommend court grant motion class certification file putative indirect purchaser class august district court grant certification class indirect purchaser september merck defendant petition appeal class certification decision fourth circuit fourth circuit deny petition september september united healthcare services inc file lawsuit district court district minnesota merck defendant uhc action uhc action make similar allegation zetia class action allegation vytorin september judicial panel multidistrict litigation transfer case eastern district virginia proceed multidistrict zetia litigation progress december humana inc file lawsuit superior court state california county san francisco merck allege defendant violate state antitrust law multiple state december centene corporation file lawsuit superior court state california county san francisco defendant humana lawsuit allege similar anticompetitive act allege zetia class action july california court rule defendant motion quash lack personal jurisdiction grant motion outofstate claim defendant order limited jurisdictional discovery regard california claim july humana centene file action merck defendant new jersey bergen county superior court reasserting claim dismiss california action september party reach agreement humana centene file claim new jersey federal court seek transfer claim multidistrict zetia litigation progress subsequently dismiss action previously file california new jersey state courts june kaiser foundation health plan inc similarly file lawsuit superior court state california county san francisco defendant humana centene kaiser lawsuit allege similar anticompetitive act allege zetia class action kaiser action remove district court northern district california july september judicial panel multidistrict litigation transfer case eastern district virginia proceed multidistrict zetia litigation progress december insurer plaintiffs kaiser humana centene multidistrict zetia litigation proceeding discovery action february united healthcare kaiser humana file amend complaint rotavirus vaccine antitrust litigation previously disclose msd defendant putative class action lawsuit file behalf direct purchaser rotateq allege violation federal antitrust law case consolidate eastern district pennsylvania january court deny msds motion compel arbitration dismiss consolidate complaint february msd appeal court order arbitration circuit october circuit vacate district court order remand limited discovery issue table content arbitrability july msd file renew motion compel arbitration plaintiff file cross motion summary judgment arbitrability november district court deny msds motion grant plaintiff motion december msd file notice appeal circuit msds appeal fully brief circuit hear argument september bravecto litigation previously disclose january company serve complaint district court district new jersey follow motion practice plaintiff file second amend complaint july seek certify nationwide class action purchaser user bravecto fluralaner product territory july plaintiff contend bravecto cause neurological event dog cat allege violation new jersey consumer fraud act breach warranty product liability relate theory company move dismiss alternatively strike class allegation second amend complaint motion pende similar case file quebec canada superior court certify class dog owner quebec give bravecto chew dog february november dog experience condition postmarkete adverse reaction section label approve november company plaintiff appeal class certification decision court appeal quebec hear appeal february take matter advisement qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery complete party file brief cross motion summary judgment currently pende court merck kgaa litigation previously disclose january protect longestablished brand right company file lawsuit merck kgaa darmstadt germany kgaa historically operate emd group allege improperly use merck kgaa file suit company france germany switzerland mexico india australia singapore hong kong sar prc china allege thing unfair competition trademark infringement andor corporate infringement australia singapore hong kong sar prc india kgaa allege breach party coexistence agreement litigation ongoe trial date set ongoing numerous jurisdiction outside patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application nda fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten table content period exclusivity product respect product acquire acquisition potentially significant intangible asset impairment charge bridion previously disclose january november company receive multiple paragraph certification letter hatchwaxman act notify company generic drug company file application fda seek prepatent expiry approval sell generic version bridion sugammadex injection march april december company file patent infringement lawsuit district court district new jersey northern district west virginia generic company action district new jersey consolidated lawsuit assert patent cover sugammadex method sugammadex automatically stay fda approval generic application june adverse court decision whichever occur early mylan pharmaceuticals inc mylan api llc mylan inc mylan file motion dismiss district new jersey lack venue failure state claim certain defendant northern district west virginia failure state claim certain defendant new jersey motion decide west virginia action stay pende resolution new jersey motion company settle generic company provide generic company bring generic version bridion market january delay applicable pediatric exclusivity early certain circumstance company agree stay lawsuit file generic company exchange agree bind judgment merit consolidate action district new jersey generic company consolidate action request dismissal action company oppose request subsequently grant court company expect company bring generic version bridion market january later depend applicable pediatric exclusivity company receive adverse court decision januvia janumet janumet previously disclose fda grant pediatric exclusivity respect januvia janumet janumet provide month exclusivity expiration patent list fdas orange book add exclusivity term key patent protection extend exclusivity product january company currently anticipate sale januvia janumet decline significantly date januvia janumet janumet contain sitagliptin phosphate monohydrate company patent cover certain phosphate salt polymorphic form sitagliptin saltpolymorph patent determine valid preclude generic manufacturer make sitagliptin phosphate salt polymorphic form expiration patent plus pediatric exclusivity par pharmaceutical file suit company district court district new jersey seek declaratory judgment invalidity saltpolymorph patent response company file patent infringement lawsuit district court district delaware par pharmaceutical additional company indicate intent market generic version januvia janumet janumet follow expiration key patent protection prior expiration saltpolymorph patent later grant patent own company cover janumet formulation term plus pediatric exclusivity end company file patent infringement lawsuit mylan northern district west virginia judicial panel multidistrict litigation enter order transfer company lawsuit mylan district court district delaware coordinate consolidated pretrial proceeding case pende district prior beginning schedule october trial district court district delaware invalidity issue company settle defendant schedule participate trial company case mylan bench trial hold december district court northern district west virginia closing argument schedule april total company settle generic company provide generic company bring generic version januvia janumet market early certain circumstance generic version janumet market july early certain circumstance table content additionally mylan file petition inter part review ipr patent trademark office uspto seek invalidity claim saltpolymorph patent uspto institute ipr proceeding find reasonable likelihood challenge claim valid trial hold february final decision render hold challenge claim invalid mylan appeal usptos decision court appeal federal circuit march company file patent infringement lawsuit district court district delaware zydus worldwide dmcc zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus lawsuit company allege infringement saltpolymorph patent base filing zyduss application seek approval sitagliptin tablet district court district delaware set threeday bench trial matter begin october germany generic company seek revocation supplementary protection certificate spc janumet generic company successful janumet lose market exclusivity germany time expiry januvia pediatric market exclusivity september hearing hold june court decide spc janumet invalid decision company appeal challenge janumet spc occur follow european country austria czech republic finland france hungary italy portugal romania slovakia sweden litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial condition result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability table content material adverse effect financial condition result operation liquidity company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period subject term applicable award psu award generally vest year rsu award generally vest onethird year threeyear period table content total pretax sharebase compensation cost record million million million respectively include million million million respectively relate continue operation income tax benefit sharebase compensation expense recognize million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree interest rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeited award transfer organon spinoff adjustment merck awards relate spinoff organon outstanding december vest expect vest december exercisable december activity prior organon spinoff restate connection spinoff organon outstanding merck stock option vest unvested convert adjust merck award current merck employee organon awards organon employee adjust award preserve intrinsic value general term condition include vest place immediately prior adjustment additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option table content summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited award transfer organon spinoff adjustment merck awards relate spinoff organon nonveste december expect vest december activity prior organon spinoff restate connection spinoff organon outstanding merck rsus psus vest unvested convert adjust merck award current merck employee organon awards organon employee adjust award preserve intrinsic value general term condition include vest place immediately prior adjustment december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expenses pension postretirement benefit plan company define benefit pension plan cover eligible employee certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plan include certain cost report discontinue operation consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset amortization unrecognize prior service cost net loss gain amortization termination benefit curtailment settlement net periodic benefit cost credit net periodic benefit cost credit pension postretirement benefit plan include expense curtailment settlement termination benefit provide certain employee connection spinoff organon connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment settlement record table content certain pension plan increase lump sum payment pension plan participant contribute settlement record component net periodic benefit cost credit service cost component include income expense net note exception certain amount termination benefit curtailment settlement record restructuring cost event give rise termination benefit curtailment settlement related restructuring action income discontinue operation net taxis amount attributable noncontrolle interest relate spinoff organon note obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement spinoff organon fair value plan asset december benefit obligation january service cost interest cost actuarial gain loss benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement spinoff organon benefit obligation december fund status december recognize asset accrue current liability noncurrent liability actuarial gain loss primarily reflect change discount rate december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total pension plan cash cash equivalent investment fund develop market equities emerge market equity mortgage assetbacked security equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment plan asset fair value international pension plan cash cash equivalent investment fund develop market equity government agency obligation emerge market equities corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total cash cash equivalent investment fund develop market equities emerge market equity government agency obligation mortgage assetbacke security equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plans benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan table content target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution contribution expect approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net gain loss arise period prior service cost credit arise period net loss gain amortization include benefit cost prior service credit amortization include benefit cost table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate interest credit rate benefit obligation discount rate salary growth rate interest credit rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis expect rate return plan develop consider longterm historical return data current market condition actual return plan asset reference information longterm return expectation asset category weightedaverage expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare range health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate saving plan company maintain define contribution saving plan company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss income investment equity security net net periodic define benefit plan credit cost service cost net include net realize unrealized gain loss investment equity security own directly ownership interest investment fund unrealize gain loss investment directly own determined end report period gain loss ownership interest investment fund account quarter lag company estimate loss approximately million record quarter ownership interest investment fund net present table include million goodwill impairment charge relate certain business healthcare service segment fully divest quarter interest pay million million million taxis income reconciliation effective tax rate income continue operation statutory rate follow tax rate tax rate tax rate statutory rate apply income continue operation taxis differential arise foreign earning gilti foreignderive intangible income deduction tax settlement tax credit acquisition velosbio acquisition pandion valuation allowance restructure acquisitionrelate cost include amortization state taxis acquisition oncoimmune acquisition peloton tax cut job act tax cut job act tcja enact december company reflect impact tcja financial statement application certain provision tcja table content remain subject interpretation certain instance company reasonable estimate effect tcja finalize result additional income tax expense company remain transition tax liability tcja reduce payment utilization foreign tax credit billion december million include income taxis payable remainder billion include noncurrent liability result transition tax tcja company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign withholding taxis apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate particularly ireland switzerland singapore puerto rico operate tax incentive grant begin expire yield favorable impact effective tax rate compare statutory rate begin company additional tax incentive form tax holiday switzerland newly active legal entity effective income continue operation taxis consist year end december domestic foreign taxis income continue operation consist year end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability product intangible license inventory relate accelerated depreciation equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer tax asset nol carryforward relate foreign jurisdiction valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward valuation allowance million establish tax credit carryforward nol carryforward income taxis pay include amount attributable discontinue operation billion billion billion respectively tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation spinoff organon balance december amount reflect settlement irs discuss include million relate divestiture merck consumer care business company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease approximately million month result audit closure settlement expiration statute limitation ultimate finalization company table content examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount benefit expense million million million amount reflect beneficial impact tax settlement include settlement discuss liability accrue interest penalty million million december respectively internal revenue service irs conclude examination merck federal income tax return result company require payment million million related continue operation million relate discontinued operation company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit million relate continue operation million relate discontinued operation net benefit reflect reduction reserve unrecognize tax benefit relate liability tax position relate year examination irs conclude examination merck federal income tax return result company require payment million million relate discontinued operation offset credit million relate continue operation company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit million relate continue operation million relate discontinued operation net benefit reflect reduction reserve unrecognize tax benefit tax position relate year examination partially offset additional reserve tax position previously reserve irs currently conduct examination company tax return year addition state foreign tax examination progress jurisdiction company income tax return open examination period earning share calculation earning share share millions follow year end december net income continue operation attributable merck inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck inc common shareholder income continue operation income discontinue operation net income issuable primarily sharebased compensation plan table content million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive comprehensive income loss change component comprehensive income loss follow foreign employee currency accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis spinoff organon note balance december net taxis primarily relate foreign currency cash flow hedge reclassify aocl sale represent net realize gain sale availableforsale debt security reclassify aocl income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer begin amortization intangible asset previously include calculation segment profit include unallocated nonsegment corporate expense prior period pharmaceutical animal health segment profit recast reflect change comparable basis company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter table content sale company product follow year end december intl total intl total intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima vaccine gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion prevymis primaxin noxafil cancidas invanz zerbaxa immunology simponi remicade neuroscience belsomra virology molnupiravir isentressisentress cardiovascular alliance revenue adempasverquvo adempas diabete januvia janumet pharmaceutical total pharmaceutical segment sale animal health livestock companion animal total animal health segment sale segment sale total segment sale plus international equal total round alliance revenue represent merck share profit product sale net cost sale commercialization cost note alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent sale healthcare service segment business healthcare service segment fully divest quarter primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacturing sale include sale organon include million relate achievement milestone outlicense product trigger contingent payment merck table content consolidated sale geographic area derive follow year end december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profit income continue operation taxis follow year end december segment profit pharmaceutical segment animal health segment segment total segment profit profit unallocate interest income interest expense amortization depreciation research development restructuring cost unallocate net pharmaceutical segment profit comprise segment sale standard cost sell general administrative expense directly incur segment animal health segment profit comprise segment sale cost sale sell general administrative expense research development cost directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur merck research laboratory companys research development division focus human healthrelated activity general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization intangible asset purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacturing sale unallocate net include expense corporate manufacturing cost center goodwill intangible asset impairment charge gain loss sale business expense income relate change estimate fair value measurement liability contingent consideration miscellaneous income expense item table content equity loss affiliate depreciation include segment profit follow pharmaceutical animal health total year end december include segment profit equity loss affiliate depreciation year end december include segment profit equity loss affiliate depreciation year end december include segment profit equity loss affiliate depreciation property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific china japan china latin america japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director stockholders merck inc opinion financial statement internal control financial reporting audit accompany consolidated balance sheet merck inc subsidiary company december relate consolidated statement income comprehensive income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report internal control financial reporting appear item responsibility express opinion company consolidate financial statement companys internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate rebate accrual medicaid manage care medicare describe note consolidated financial statement company record certain variable consideration include discount estimate time sale generally expect value method amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue certain discount represent portion accrual form rebate amount owe base definitive contractual agreement legal requirement private sector manage care public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider management use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision accrue balance relative provision rebate include accrue current liability billion december majority relate rebate accrual medicaid manage care medicare principal consideration determination perform procedure relate rebate accrual medicaid manage care medicare critical audit matter significant judgment management significant measurement uncertainty involve develop rebate accrual accrual base assumption develop pricing information historical customer segment utilization mix high degree auditor judgment subjectivity effort perform procedure evaluate evidence relate assumption address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate rebate accrual medicaid manage care medicare include management control assumption estimate correspond rebate accrual procedure include develop independent estimate rebate accrual utilize party datum historical customer segment utilization mix pricing information term specific rebate program historical trend actual rebate claim pay compare independent estimate rebate accrual record management iii testing rebate claim pay include evaluate claim consistency contractual term company rebate agreement pricewaterhousecooper llp florham park new jersey february serve company auditor table content supplementary datum select quarterly financial datum unaudite million share amount sale gross profit net income continue operation attributable merck inc loss income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder income continue operation loss income discontinue operation net income earning common share assume dilution attributable merck inc common shareholder income continue operation loss income discontinue operation net income sale gross profit net loss income continue operation attributable merck inc income discontinue operation net taxis amount attributable noncontrolle interest net loss income attributable merck inc basic loss earning common share attributable merck inc common shareholder loss income continue operation income discontinue operation net loss income loss earning common share assume dilution attributable merck inc common shareholder loss income continue operation income discontinue operation net loss income amount fourth quarter include charge relate acquisition velosbio inc oncoimmune note intangible asset impairment charge relate zerbaxa note amount quarter include charge relate transaction seagen inc note amount second quarter include charge relate acquisition pandion therapeutics inc note reflect result business spunoff organon june discontinue operation period present note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective fourth quarter change internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate table content framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear robert davis caroline litchfield chief executive officer president executive vice president chief financial officer item information item disclosure foreign jurisdiction prevent inspection applicable table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section securities exchange act applicable incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website merckcomcompanyoverviewculture andvaluescodeofconductvaluesandstandard company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate schedule director fee table director compensation table company proxy statement annual meeting shareholder hold require information heading compensation management development committee interlock insider participation compensation management development committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck inc incentive stock plan merck inc nonemployee directors stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item